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Tumour necrosis factor alpha (TNFα) is a pleiotropic cytokine and has a wide variety 
of dose dependent cellular effects ranging from cell growth and differentiation, to 
inducing apoptosis. It has long been implicated in muscle and non-muscle 
inflammatory disorders, such as muscle wasting in chronic disease states, and 
rheumatoid arthritis. However, a physiological role for TNFα in muscle regeneration 
has been proposed as elevated levels of the cytokine are present when muscle 
regeneration processes are initiated: TNFα is secreted by infiltrating inflammatory 
cells, and by injured muscle fibres. Adult skeletal muscle contains a population of 
resident stem cell-like cells called satellite cells, which become activated, proliferate 
and differentiate following muscle injury to bring about repair of damaged muscle. 
Much research on the effects of TNFα on satellite cell differentiation has been 
conducted in recent years. It is however difficult to get a complete characterisation of 
the cytokine’s action as all models used slightly differ. We aimed therefore at providing 
comprehensive assessment of the effects of increasing doses of chronically 
supplemented TNFα on differentiating C2C12 cells. Cells were allowed to differentiate 
with or without TNFα supplementation for 7 days. Differentiation was induced at day 
0. The effect on differentiation was assessed at days 1, 3, 5, and 7 by western blot 
analysis, and supplementary immunohistochemical analysis at days 1, 4, and 7 of 
markers of differentiation - muscle regulatory factors: MyoD and myogenin, markers of 
the cell cycle p21, PCNA, and the integral signalling molecule, p38MAPK. TNFα 
supplementation at day 1 tended to positively regulate early markers of differentiation. 
With continued supplementation however, markers of differentiation decreased dose 
dependently in treated cultures as the initial effect appeared to be reversed: A trend 
towards a dose dependent decrease in MyoD, myogenin and p21 protein existed in 
treated cultures at days 3, 5, and 7. These findings were significant at day 5 (p21, 
p<0.05), and day 7 (myogenin, p<0.05). A significant dose dependent decrease in p38 
phosphorylation was evident at day 3 (p<0.05), while phospho-p38 was dose 
dependently increased at day 7 (p<0.05). Taken together, these data show that TNFα 
supplementation for 24 hours following the induction of differentiation in vitro, tends 
to increase levels of early markers of differentiation, and with continued TNFα 
supplementation decrease markers of differentiation in a dose dependent fashion. This 
study provides a comprehensive characterisation of the dose and time dependent effects 
of TNFα on satellite cell differentiaton in vitro. The model system used in the current 
study, allows us to make conclusions on more chronic disease states. 
Tumor nekrose faktor alfa (TNFα) is ‘n pleiotropiese sitokien wat ‘n wye 
verskeidenheid, dosis afhanklike, sellulêre effekte te weeg bring. Hierdie sellulêre 
effekte sluit sel groei en differensiasie tot sel dood in. TNFα is by beide spier en nie-
spier inflammatoriese stoornisse soos spier tering in kroniese siektetoestande, en 
rumatiese artritis betrek. ‘n Fisiologiese rol vir TNFα is egter voorgestel aangesien 
verhoogde vlakke van die sitokien tydens inisiasie van spier herstel meganismes 
teenwoordig is: TNFα word deur infiltrerende inflammatoriese selle, asook deur 
beseerde spier vesels afgeskei. Volwasse skeletspier bevat ‘n populasie stamselagtige 
selle, sogenoemde satelliet selle. Laasgenoemde word geaktiveer, prolifereer en 
differensieër volgende spierbesering, om sodoende herstel van beskadigde spier te 
weeg te bring. Baie navorsing op die effekte van TNFα op satelliet sel differensiasie is 
onlangs uitgevoer. Dit is egter aansienlik moeilik om volgens hierdie navorsing‘n 
algehele beeld van TNFα se aksies te vorm aangesien alle modelle wat gebruik word 
verskil. Ons doel was daarom om ‘n omvangryke assessering van toenemende 
konsentrasies kronies gesupplementeerde TNFα op differensieërende C2C12 selle op ‘n 
enkele model uit te voer. Selle was vir 7 dae met of sonder TNFα supplementasie 
gedifferentieër. Differensiasie was by Dag 0 geïnduseer. TNFα se effek op 
differensiasie is op dae 1, 3, 5, en 7 deur middel van western blot analise geassesseer. 
Aanvullende immunohistochemiese bepalings op dae 1, 4, en 7 is verder deurgevoer. 
Merkers vir differensiasie het die spier regulatoriese faktore MyoD en miogenien, sel 
siklus merkers p21 en PCNA, asook die integrale sein transduksie molekule p38MAPK 
ingesluit. TNFα supplementasie by dag 1 het geneig om vroeë merkers van 
differensiasie positief te reguleer. Met voortdurende supplementasie is die vroeë 
positiewe effekte (op ‘n dosis afhanklike manier) egter omgekeer: ‘n neiging teenoor 
(‘n dosis afhanklike) vermindering in MyoD, miogenien en p21 proteïen het in 
behandelde kulture op dae 3, 5, en 7 bestaan. Hierdie bevindinge was beduidend by dag 
5 (p21, p<0.05), en dag 7 (miogenien, p<0.05). A beduidende dosis afhanklike afname 
in p38 fosforilasie was duidelik by dag 3 (p<0.05), terwyl fosfo-p38 by dag 7 verhoog 
het met verhoogde konsentrasie TNFα (p<0.05). Bogenoemde saamgevat, dui aan dat 
TNFα supplementasie 24h volgende die induksie van differensiasie in vitro, verhoogde 
vlakke van vroeë differnsiasie merkers te weeg bring. Met voortdurende TNFα 
supplementasie, word differensiasie merkers egter met toenemende dosis verminder. 
Hierdie studie voorsien ‘n omvattende karakterisering van die dosis- en tyd afhanklike 
effekte van TNFα op satelliet sel differesiasie in vitro. Die model sisteem in hierdie 
studie gebruik, maak afleidings oor meer kroniese siektetoestande moontlik. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Skeletal muscle 
 
1.1.1 Skeletal muscle morphological structure (general overview) 
Adult skeletal muscle is composed of postmitotic, multinucleated (Morgan et al., 2003) 
elongated cells known as muscle fibres (myofibres) (Charge et al., 2004; Vander et al., 
2001). Muscle fibres are grouped and arranged into bundles known as fasciculi, clearly 
visible at cross section through skeletal muscle (Figure 1.1 A). An extensive connective 
tissue network is found within skeletal muscle: Each muscle fibre is individually 
surrounded by connective tissue known as the endomysium, each myofibre bundle by 
the perimysium, while the epimysium surrounds an entire muscle (McComas, 1996). 
Skeletal muscle is richly supplied of essential nutrients by a network of blood vessels 
dispersed throughout the perimysium (Charge et al., 2004). At the end of each muscle 
collagen fibres (tendons) connect the muscle to bone, allowing whole muscle 
shortening and synchronised contraction and force generation (McComas, 1996). 
Effective force generation and muscle contraction is the product of each of the muscle 
components. This is adequately illustrated in individuals where a single defective or 
missing muscle component (such as the affected dystrophin gene in muscular 
dystrophy sufferers) severely affects muscle function. 
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Figure 1.1 Basic organisation of skeletal muscle. A cross section of skeletal muscle, 
showing muscle fiber bundles (fasciculi) (A). A single muscle fiber bundle consisting 
of myofibers (B). Satellite cell position within muscle (C). Figure adapted and modified 
from Hawke & Garry (2001). 
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myonucleus 
Satellite cell basal lamina 
perimysium 
epimysium 
fasciculi 
endomysium 
myofiber 
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1.1.2 Contractile apparatus and force generation of skeletal muscle 
Myofibres contain the basic contractile units of skeletal muscle, the sarcomere. A 
significant portion of cytoplasm is filled with so called thick and thin filaments neatly 
arranged into cylindrical bundles referred to as myofibrils (Figure 1.1 B) and are 
concerned with the contractile function of the muscle cell (McComas, 1996). Muscle 
contraction, or shortening, is brought about by a sliding mechanism whereby the 
myosin rich thick filaments and actin rich thin filaments slide over each other and 
shorten the muscle upon stimulation (Charge et al., 2004). 
 
1.2. Skeletal muscle function and integrity  
Skeletal muscle (SM) is chiefly involved in the facilitation of locomotor activity, 
breathing, and coordinated and directed movements (Charge et al., 2004; Song et al., 
1998). By virtue of its function, SM is rather susceptible to injury, however, despite the 
challenges SM faces during the daily cycle of use, it remains a relatively stable tissue, 
with little turnover of nuclei (Charge et al., 2004). Adult SM has a remarkable 
capability to self-repair in response to the physiological demands of growth, training 
and injury (Hawke et al., 2001). It has been said that maintaining an efficiently 
working skeletal musculature is granted by its notable ability to regenerate (Charge et 
al., 2004). 
 
As skeletal myofibers are highly specialised and terminally differentiated, their 
regeneration requires some source of renewable cells capable of myogenic 
differentiation (Zammit et al., 2001). The identification of so-called muscle satellite 
cells by Mauro in 1961 (Mauro, 1961) led to great advances in our understanding of 
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muscle regeneration as it became clear that satellite cells are indeed that renewable 
source of cells. This is responsible for all postnatal muscle growth, hypertrophy and 
differentiation are accomplished by satellite cells (Blau et al., 2001; Hawke et al., 
2001; Seale et al., 2000a). 
 
1.3. Satellite cells (stem cell like progenitors of skeletal muscle) 
Satellite cells were initially described and named according to their location relative to 
the mature myofibre. Residing between the basal lamina and the sarcolemma, satellite 
cells occupy indentations on the periphery of myofibres (Figure 1.1 C) (Charge et al., 
2004; Hawke et al., 2001; Mauro, 1961; Morgan et al., 2003; Muir et al., 1965; Seale 
et al., 2000a). They exist as a pool of mononucleated, undifferentiated, stem cell-like 
cells (Hawke et al., 2001). Stem cells are referred to as non-specialized cells capable of 
self-renewal and of differentiation along multiple lineages. Cells from the first two 
divisions of the zygote are totipotent, which means that any cell type from the embryo 
as well as cells from the placenta can be formed from them (Alison et al., 2002). A 
second type of stem cell, the embryonic stem cell (ES), has the potential to form any 
cell type from the three germ layers: meso-, endo-, and ectoderm. ES are however not 
capable of forming the placenta, and can therefore not form a new embryo (Alison et 
al., 2002). The third type of stem cell, the so called adult stem cell, is resident in most 
organs of mature animals. By acting as a source of new cells, adult stem cells are 
responsible for postnatal growth and repair (Blau et al., 2001). Satellite cells are 
referred to as stem cell-like cells as they too, are undifferentiated and self-renewing. 
Furthermore, they have been shown to be able to differentiate into adipogenic cells as 
well (Asakura et al., 2001). 
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In their un-activated state, satellite cells are said to be quiescent and divide 
infrequently. As stem cells undergo a limited number of cell divisions, chances of 
accumulating mutations during DNA replication are reduced (Alison et al., 2002). Such 
an inactive state does not however imply a totally inactive basal state, but rather a state 
in which only limited maintenance genes are expressed. The difficulty of studying 
satellite cell populations in vivo lies with their small population size in muscle, and is 
further hindered by the fact that a mere isolation process is stimulus enough for their 
activation and subsequent proliferation (Charge et al., 2004). 
 
Quiescent satellite cells express a distinct set of markers (See Appendix A for table of 
satellite cell markers), and are distinguished from adult myoblasts by various 
morphological characteristics, including their reduced organelle number, and increased 
nuclear-to-cytoplasmic ratio. Relative to the neighbouring myonucleui, quiescent 
satellite cells nuclei are small with increased amounts of heterochromatin (highly 
condensed regions on chromosomes physically obstructing the binding of transcription 
and other factors). Such characteristics are indicative of the fact that satellite cells 
(when unstimulated), are mitotically quiescent and metabolically- and transcriptionally 
less active (Charge et al., 2004; Hawke et al., 2001). 
 
1.3.1 Studying skeletal muscle differentiation in vitro 
Following the appropriate cues (see further sections), satellite cells become activated, 
and initiate multiple rounds of proliferation, and subsequently differentiate into mature 
myofibers (Charge et al., 2004; Hawke et al., 2001). The major muscle differentiation 
steps can be reproduced in vitro with the aid of muscle satellite cell lines (Charge et al., 
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2004; Hawke et al., 2001). Differentiation is induced by a process of serum removal, a 
process whereby the serum concentration of culture medium is dropped considerably. 
The C2C12 murine skeletal muscle cell line (amongst other) is commonly used to study 
myogenesis in vitro. Primary tissue cultures are also often employed by researchers. 
 
1.3.2 Cell cycle 
 
1.3.2.1 Overview of the cell cycle 
Cellular events that take place from the completion of one division until the start of the 
following division constitute the cell cycle (Klug et al., 2000). Cells spend most of 
their time in interphase, the initial stage of the cell cycle. Interphase is further 
subdivided into 3 phases namely the G1, S, and G2 phases. At an advanced point in G1 
phase cells continue on one of two paths: either proceeding to S phase and DNA 
replication, or entering what is known as G0 phase. Despite not proliferating, cells in 
G0 remain metabolically active (Schafer, 1998) and are referred to as quiescent. 
Tremendous metabolic activity and cell growth take place throughout interphase 
(Vander et al., 2001). Following the S phase, physical cell division (both nuclear and 
cytoplasmic) occurs during the M, or mitosis stage of the cell cycle. It is therefore only 
in the mitosis stage of the cell cycle that any visible signs of division become evident. 
Proliferating cellular nuclear antigen (PCNA) is an accessory factor to DNA 
polymerase and is, as such, used as a marker of cell proliferation (Layne et al., 1999; 
Schafer, 1998; Seale et al., 2000a). 
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1.3.2.2 Regulation of the cell cycle 
The cell cycle is under strict regulation. Several so called checkpoints have been 
identified within the cell cycle. Depending on the condition of the cell at these 
checkpoints, a decision to proceed with or halt the cycle beyond the checkpoint is 
effected. Cyclin dependent kinases (cdk) are the major promoters of cell cycle 
progression. Their action (moving cells through the various phases) is dependent on the 
interaction with different subsets of subunits of a group of proteins known as cyclins of 
which cyclin D1 is a well studied example (Guo et al., 1995; Hawke et al., 2001; 
Schafer, 1998). Cdk inhibitors negatively regulate cell progression by adhering to 
cdk/cyclin complexes, thereby blocking their action. Five cdk inhibitors have been 
identified to date: p15, p16, p18, p21, and p27 (Peter et al., 1994). 
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Figure 1.2 The cell cycle. See text for details. 
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G1 
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G2 
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1.3.3 The activation of satellite cells  
In response to a wide variety of stimuli including denervation, stretching, over exertion, 
agents released from damaged tissue and the inflammatory response resultant of muscle 
damage (Grounds, 1998) satellite cells exit their normal quiescent state, enter the cell 
cycle, (i.e. move from G0 to G1 phase of cell cycle) and initiate multiple rounds of 
proliferation. Once proliferating, satellite cells are referred to as adult myoblasts or 
myogenic precursor cells (mpc) (Charge et al., 2004). Following multiple rounds of 
proliferation, most of the myoblasts migrate to the injured fibre where they either fuse 
to the existing myofiber (thereby progressing muscle repair), or together to form a new 
myofiber. Recent reports have, however, indicated that certain satellite cells already 
fuse after only 1 or 2 cell divisions (Schultz, 1996). The remainder of the activated 
satellite cell population once again become quiescent, thereby completing the process 
of self-renewal. Such a process is vital in preventing depletion of the satellite cell pool 
(Charge et al., 2004). 
 
1.3.4 Activated satellite cells at the molecular level  
At a molecular level, the activation of satellite cells is accompanied by a rapid up-
regulation of two groups of myogenic transcription factors that are important for 
myogenesis: the myogenic regulatory factor (MRF) family and the myocyte enhancer 
binding factor 2 (MEF2) family of proteins (Charge et al., 2004; Wu et al., 2000). 
 
1.3.5 The myogenic regulatory factor (MRF) family of transcription factors 
The MRFs, a family of basic helix loop helix (bHLH) transcription factors consists of 
the Myf5, MyoD, myogenin and MRF4 proteins (Charge et al., 2004; Sabourin et al., 
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2000; Seale et al., 2000a; Song et al., 1998; Zhou et al., 1994) that are all found 
specifically in skeletal muscle (Wu et al., 2000). Quiescent satellite cells have no 
detectable expression of the MRFs, but activated satellite cells are characterised by 
their rapid up-regulation (Charge et al., 2004; Sabourin et al., 1999; Seale et al., 
2000a). The MRFs drive the myogenic differentiation program at molecular level to 
bring about satellite cell differentiation into mature myotubes. The temporal MRF 
expression patterns during satellite cell activation, proliferation and differentiation 
during muscle regeneration are comparable to those during embryogenesis (Seale et al., 
2000a). As transcription factors, the MRF mode of action involves the induction of 
muscle-specific gene transcription. The bHLH transcription factors heterodimerise with 
other bHLH proteins before binding to a site (referred to as an E-box) in the promoter 
region of muscle specific genes (Sabourin et al., 2000; Wu et al., 2000). 
 
The MyoD and Myf5 transcription factors are considered the primary MRFs, 
responsible for the commitment of satellite cells to myogenic differentation. The 
secondary MRFs, myogenin and MRF4 are responsible for the regulation of terminal 
differentiation (Sabourin et al., 2000; Seale et al., 2000a). 
 
1.3.5.1 Primary myogenic regulatory factors: Myf 5 and MyoD 
Activated satellite cells express either Myf5 or MyoD initially, before coexpressing 
both MyoD and Myf5 (Cornelison et al., 1997; Sabourin et al., 2000; Seale et al., 
2000a). Interestingly, mice with a homozygous deletion of MyoD develop normally, 
however mice lacking both MyoD and Myf5 do not form skeletal muscle (Rudnicki et 
al., 1992). 
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However, in the absence of MyoD, less activated myogenic progenitors progress 
through the differentiation program (Seale et al., 2000a). Myf5 on the other hand plays 
an important role as a molecular determinant of satellite cell self-renewal (Charge et 
al., 2004; Sabourin et al., 2000; Seale et al., 2000b). 
 
MyoD is a key factor to the commitment of myoblasts to the differentiation program, 
and is greatly expressed in activated, proliferating myoblasts transitioning to 
differentiation (Charge et al., 2004; Sabourin et al., 2000; Seale et al., 2000a). Besides 
activating muscle specific genes during myogenesis, MyoD expression also leads to 
cell cycle arrest (Song et al., 1998); in a mechanism thought to involve transcriptional 
activation of the gene coding for the cell cycle inhibitor p21 (Langen et al., 2004; 
Parker et al., 1995; Sabourin et al., 2000). This draws attention to an important 
consideration: Upon stimulation, the myogenic differentiation program is initiated in 
myoblasts, whereby expansion of the myogenic pool takes place, thus ensuring the 
provision of many new myonuclei for fusion and new myotube formation. Although 
myoblasts do undergo multiple rounds of proliferation upon activation, cell cycle exit is 
however required for myogenic differentiation, as proliferation and differentiation are 
two mutually exclusive events (i.e. mitogenic vs. myogenic stimuli) (Andres et al., 
1996). 
 
1.3.5.2 Secondary myogenic regulatory factors 
The secondary MRFs are required downstream of MyoD and Myf 5 to further the 
differentiation of myoblasts into mature myofibers. Sequential up-regulation of 
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myogenin and MRF4 therefore takes place in myoblasts entering their terminal 
differentiation phase (Charge et al., 2004; Hawke et al., 2001; Sabourin et al., 2000). 
Cell cycle arrest proteins (such as p21) are irreversibly activated allowing myoblasts to 
permanently exit the cell cycle (Charge et al., 2004; Sabourin et al., 2000; Song et al., 
1998). 
 
While myogenin promotes the transcription of muscle-specific genes, the proposed role 
for MRF4 in the myogenic program appears to be extended beyond that of myogenin. 
MRF4 expression is found in myonuclei of newly formed myotubes and regenerated 
myofibres, at a time after fusion. It is therefore suspected to play a role in myofibre 
maturation (Charge et al., 2004; Zhou et al., 2001). 
 
1.3.6 The MEF2 family of proteins 
The MEF2 family of transcription factors binds directly to the promoters of most 
muscle-specific genes at A/T (Adenine/Thymine) rich DNA sequences. The MEF2 
proteins act in conjunction with the MyoD transcription factors specifically, to initiate 
the skeletal muscle differentiation program (McKinsey et al., 2002). 
 
1.4 Response of satellite cells to muscle injury: role of growth factors 
Skeletal muscle damage (myotrauma) ranges from macromolecule damage to tears in 
the sarcolemma, basal lamina and the supportive connective tissue, or even the 
contractile proteins of the myofiber (Vierck et al., 2000). Direct physical trauma can be 
brought about by extensive physical exercise like resistance training, or lengthening 
contractions that lead to functional and histological signs of injury (Charge et al., 2004; 
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Toumi et al., 2003; Tsivitse et al., 2005; Vierck et al., 2000). Severe muscle injuries 
can be induced by either extreme cold; crushing, or toxins (Warren et al., 2002). 
Indirect causes of muscle injury include inherent genetic defects (muscular dystrophies 
for example), (Charge et al., 2004). 
 
Damage to the myofiber leads to the release of a milieu of growth factors, cytokines 
and other agents and mediators from both the injured tissue as well as from the 
inflammatory response following injury (Shephard et al., 1998; Tidball, 2002; Toumi et 
al., 2003; Vierck et al., 2000). 
 
1.4.1 Growth factors/agents released from injured muscle following myotrauma 
The growth factors referred to include hepatocyte growth factor (HGF); fibroblast 
growth factors (FGFs); insulin-like growth factors (IGFs); transforming growth factor 
beta TGFβ, and Interleukin (IL)-6 family of cytokines, including leukaemia inhibitory 
factor (LIF). Many of the agents released from the damaged area act as messengers and 
are chemo-attractants to inflammatory- and satellite cells (Bischoff, 1997; Vierck et al., 
2000). Platelet activating factor (Shephard et al., 1998), myostatin, neural derived 
factors, nitric oxide, testosterone as well as ATP are other factors seem to play a role in 
the emerging picture of muscle regeneration (Charge et al., 2004; Hawke et al., 2001; 
Seale et al., 2000a; Vierck et al., 2000). 
 
1.4.1.1 Hepatocyte Growth Factor (HGF) 
HGF, first identified as being a mitogen for mature hepatocytes (Hawke et al., 2001), is 
now considered imperative to regulating satellite cells following muscle damage. It is 
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particularly important in the early phases of regeneration where it serves as a chemo-
attractant to satellite cells (Bischoff, 1997; Hawke et al., 2001), and stimulates the 
quiescent satellite cell to enter the cell cycle and commence proliferation (Charge et al., 
2004; Hawke et al., 2001). HGF is released from the damaged myofibre during the first 
three days following injury (Jennische et al., 1993) at levels directly proportional to the 
degree of injury (Hawke et al., 2001; Tatsumi et al., 2001; Vierck et al., 2000). Its 
receptor, c-met, is expressed on quiescent satellite cells (Cornelison et al., 1997; 
Hawke et al., 2001), myoblasts and adjacent myofibres (Hawke et al., 2001). 
 
Although the HGF/c-met pathway is important for expanding the mpc population 
during the early stage of regeneration, down regulation of this pathway (and mostly all 
mitogenic stimuli) is necessary for differentiation to commence (Coolican et al., 1997; 
Wu et al., 2000). 
 
1.4.1.2 Fibroblast Growth Factors (FGFs) 
Nine different isoforms of FGF have been identified, (Hawke et al., 2001) of which 
FGF-6 is muscle specific (Floss et al., 1997), and up-regulated in response to muscle 
damage (Floss et al., 1997). Although FGF’s precise role in muscle regeneration 
remains unclear (Charge et al., 2004), its regulation of the satellite cell population is 
analogous to that of HGF in that it promotes proliferation of the mpc population 
without increasing their subsequent differentiation (Charge et al., 2004; Hawke et al., 
2001). 
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Both FGF and HGF receptors (FGFR and c-met respectively) are transmembrane 
receptor tyrosine kinases (Charge et al., 2004) that dimerise upon ligand binding, 
become auto-phosphorylated and subsequently activate downstream signalling events. 
 
1.4.1.3 Insulin-like Growth Factors (IGFs) 
IGF-I and –II play an important role in the growth and development of various tissues, 
and are up-regulated during muscle regeneration. IGF-I and –II promote both 
expansion of the myogenic pool as well as differentiation of myoblasts in vitro. IGF-I 
may promote muscle regeneration by promoting satellite cell differentiation and cell 
survival, chiefly through a phosphatidylinositol 3-kinase (PI3K) pathway (Charge et 
al., 2004; Coolican et al., 1997; Hawke et al., 2001). 
 
1.4.1.4 IL-6 family of cytokines 
IL-6 and LIF are members of an IL-6 family of cytokines expressed both by myoblasts 
and macrophages (part of the immune system – see section below). While LIF 
promotes proliferation of satellite cells, IL-6 function involves (amongst others) 
degradation of necrotic tissue, and synchronising the cell cycle in satellite cells (Hawke 
et al., 2001). 
 
All the abovementioned growth factors (together with the agents released as part of the 
inflammatory reaction – discussed below) are necessary for the activation, chemotaxis 
and proliferation of satellite cells in a temporal and concentration-dependent manner. 
The concentrations of these factors are only transiently increased following acute injury 
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as differentiation can only occur once these growth factors have been withdrawn (ie 
mitogenic vs myogenic stimuli). 
 
1.5 Inflammation is necessary for muscle regeneration  
The immune response to infection is analogous to the immune response elicited by 
muscle damage (Vierck et al., 2000). Depending on the extent of damage, and the 
ensuing inflammatory response, inflammation can be considered a functionally 
beneficial response. Growth factors and cytokines released from injured muscle fibres 
(described above) are responsible for activating local inflammatory cells residing in the 
muscle, that in turn, chemotactically attract circulating inflammatory cells (Rappolee et 
al., 1992; Tidball, 1995) and satellite cells (Vierck et al., 2000) to the site of injury. 
 
1.5.1 Neutrophils and macrophages govern an immune response to myotrauma  
The early phase of muscle injury is characterized by the activation and rapid invasion 
of the injured muscle by inflammatory cells (Charge et al., 2004; Hawke et al., 2001; 
Seale et al., 2000a; Shephard et al., 1998; Tidball, 2002; Vierck et al., 2000). 
 
Neutrophil numbers are particularly increased at the site of damage within an hour of 
the injury (Anastasi et al., 1997; Toumi et al., 2003). First to arrive at the site of injury, 
neutrophils have a phagocytic function (Lowe et al., 1995; Shephard et al., 1998), and 
release proteases and reactive oxygen species (ROS) that serve to degrade the cellular 
debris resultant of muscle damage. Although removal of cellular debris is an important 
contribution to muscle regeneration, neutrophils can be harmful to muscle as 
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neutrophil-derived ROS and proteases molecules damage healthy tissues as well 
(Tidball, 2002; Toumi et al., 2003). 
 
Following neutrophil infiltration, macrophages become the dominant inflammatory cell 
peaking around 48h post-injury (Charge et al., 2004; Hawke et al., 2001; Orimo et al., 
1991; Tidball, 1995). Similar to neutrophils, macrophages phagocytose cellular debris 
(Charge et al., 2004; Seale et al., 2000a; Shephard et al., 1998; Vierck et al., 2000) and 
necrotic myofibers as well (Hawke et al., 2001). Macrophages play a central role in the 
immune response to myotrauma, and are a rich source of leukotrienes, prostaglandins, 
various growth factors and cytokines such as IL-1, ,IL-6, IL-8, IL-10, IL-12, LIF, 
interferon-β, and importantly, TNFα (Hawke et al., 2001; Shephard et al., 1998; 
Tidball, 2005; Vierck et al., 2000). The proinflammatory cytokine tumour necrosis 
factor alpha (TNFα) is produced in large amounts by activated macrophages 
(Saghizadeh et al., 1996), and has been recognised as a mitogenic (Li, 2003) factor for 
myoblasts. TNFα and its dose dependent effects on satellite cell differentiation is the 
central focus of this thesis. 
 
1.6 TNFα as a relevant factor in muscle adaptation and regeneration  
TNFα is barely detectable in the serum of healthy individuals at picogram-per-milliliter 
levels (Li et al., 2000; Parissis et al., 1999). Myocytes are a source of TNFα as they 
constitutively synthesize the cytokine, as do healthy human and rat skeletal muscle 
tissue (Kuru et al., 2003; Li, 2003; Saghizadeh et al., 1996). Following muscle injury, 
TNFα expression largely increases (Broussard et al., 2003; Collins et al., 2001; Warren 
et al., 2002); from two sources (Li, 2003): Macrophages infiltrate the damaged area and 
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also release TNFα as part of the inflammatory response (discussed previously). TNFα 
mRNA levels are up regulated for 24 – 48 hours before returning to basal levels in 
C2C12 cells given a differentiation stimulus (i.e. serum withdrawal) (Li et al., 2001b). 
Furthermore, circulating TNFα levels are found to increase markedly following 
strenuous exercise in healthy individuals (Camus et al., 1998; Ostrowski et al., 1999). 
At the same time, TNFα expression is increased in injured muscle fibers (De Bleecker 
et al., 1999). The up-regulation of TNFα expression by injured muscle is not merely a 
response to inflammation as it is not proportionately associated with the grade of 
inflammation (Li, 2003). Since elevated levels of TNFα are present at the time when 
muscle regeneration processes are initiated, the cytokine can be considered a relevant 
factor in skeletal muscle regeneration and adaptation. 
 
TNFα is expressed as a 26kDa integral transmembrane precursor from which a soluble 
17kDa subunit is proteolytically cleaved and released (Natoli et al., 1998; Warren et 
al., 2002). As key mediator of the inflammatory response, TNFα is known to play 
important roles in (amongst others) the chemotaxis of leukocytes, the expression of 
adhesion molecules on neutrophils and endothelial cells, and the regulation of 
production of other pro-inflammatory cytokines (Collins et al., 2001). When blocking 
TNFα, the production of other pro-inflammatory cytokines such as IL-1;-6, and-8 is 
inhibited (Butler et al., 1995; Haworth et al., 1991). TNFα could therefore be pictured 
at the very apex of a cytokine cascade such that many major pro-inflammatory 
cytokines are linked in cascade to it (Andreakos et al., 2002). As chronically elevated 
levels of TNFα are associated with chronic inflammatory diseases such as rheumatoid 
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arthritis, many treatment strategies are aimed against the cytokine due to the very fact 
that it is at an apex of a pro-inflammatory cytokine cascade (Andreakos et al., 2002). 
 
In addition to being a prime mediator of the immune system, TNFα is also implicated 
in growth and differentiation of many cell types (Li, 2003; Li et al., 2001b; Tracey et 
al., 1993). It has for example been shown that TNFα elicits a hypertrophic growth 
response in cardiac myocytes, a cell type comparible to skeletal myocytes (Yokoyama 
et al., 1997). 
 
1.7 TNF Receptors  
The diverse range of effects of TNFα are mediated by two distinct transmembrane cell 
surface receptors, TNFR-1 (also known as p55TNFR, p60, CD120a) and TNFR-2 (also 
known as p75TNFR, p80, CD120b) (Li et al., 2001a; MacEwan, 2002; Natoli et al., 
1998; Sack, 2002). Both receptors are expressed simultaneously on virtually all cell 
types (Natoli et al., 1998). TNFR are transmembrane receptors (MacEwan, 2002) that 
signal as homotrimers upon ligand (TNFα) binding (Baker et al., 1996; Balkwill, 
2000). TNFα ligand is itself presented in a trimerised form (Natoli et al., 1998). Signal 
transduction following ligand binding occurs mainly via TNFR1, where signalling 
through TNFR2 remains less well characterized (Natoli et al., 1998; Sack, 2002). 
 
1.7.1 TNF signalling activates both pro-survival and pro-apoptotic pathways 
The cytoplasmic domain of TNFR1 contains a so-called death domain (DD) to which a 
number of associating transducer molecules, each with their respective DDs, bind and 
thereby signal cell death (MacEwan, 2002). TNF receptor–associated death domain 
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(TRADD) is a vital adaptor to TNFR1 as it recruits further downstream transducers: 
Fas-associated death domain (FADD), TNF receptor-associating factor 2 (TRAF2) and 
receptor interacting protein (RIP) (Gaur et al., 2003; MacEwan, 2002; Natoli et al., 
1998) (Figure 1.3). 
 
FADD carries out the cell death action associated with TNFR1 by interacting with the 
death circuitry, including caspase-8, through its own death effector domain (DED). 
Caspases are cysteine-aspartate-directed proteases responsible for apoptotic cell death 
via destruction of “the cell’s own repair mechanisms”. Caspases-2, -8, -9, and -10 are 
so-called apoptotic initiator caspases, whereas caspases -3, -6, and -7 are executioner 
caspases and responsible for carrying out cell death mechanisms (MacEwan, 2002). 
 
TRAF2 and RIP, on the other hand, are not involved in the induction of cell death. 
TRAF2 also interacts directly with TNFR2, thereby forming a link between TNFR1, 
and -2 and explains the somewhat overlapping responses seen between the two 
receptors (Natoli et al., 1998). 
 
TRAF2 is required for the activation of two further downstream signalling molecules 
(MacEwan, 2002; Natoli et al., 1998). Interaction of the protein kinase nuclear factor 
kappa B (NFκB)-inducing kinase (NIK) with TRAF2 leads to the phosphorylation and 
subsequent inactivation of the NFκB inhibitory subunit (IκBα). This sets into motion 
the activation of the transcription factor NFκB and its subsequent translocation to the 
nucleus where it regulates transcription of genes involved in (amongst others) immune 
responses, anti-apoptosis responses, as well as cell growth and proliferation (Gaur et 
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al., 2003; Hsu et al., 1996; Li et al., 2001a; MacEwan, 2002). RIP does contain a 
kinase sequence, but its role as kinase has not yet been ascertained (MacEwan, 2002). 
RIP has however been linked to NFκB activation (Devin et al., 2003; MacEwan, 2002). 
 
The second pathway activated by TRAF2 involves the activation of the stress activated 
protein kinases (SAPK), p38 MAPK and JNK (MacEwan, 2002; Natoli et al., 1998). 
Activated SAPK phosphorylate a number of transcription factors including c-Jun, 
activating transcription factor-2 (ATF2), and AP-1 (Natoli et al., 1998), and MEF2 
(Ono et al., 2000). 
 
TNFR1 stimulation therefore leads to antagonistic signals in the target cell. Whilst cell 
death is signalled for through FADD, gene transcription is activated through TRAF2-
dependent pathways (Figure 1.3). How the fate of a cell (i.e. cell death vs. gene 
transcription) is ultimately determined remains to be elucidated. Although NFκB is 
activated within minutes of TNF receptor activation, the transcription and translation of 
cytoprotective genes would take far longer than it would the cell death circuitry to 
become effective. Yet, most cells are resistant to apoptosis except when TNF is co-
supplemented with protein/RNA synthesis inhibitors such as cycloheximide. It follows 
that cytoprotective messages independent of NFκB exist in the cell. Signals inhibiting 
the cell death machinery are another possibility considered for explaining 
cytoprotective signals dominating those of cell death (Natoli et al., 1998). 
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Figure 1.3 TNFα signalling induces both pro-apoptotic and pro-survival pathways. 
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1.7.2 Other signalling effects in response to TNFR stimulation 
TNFRs interact with an adaptor protein called neutral SMase activation factor (FAN), 
which is responsible for the degradation of sphingolipids into ceramide-containing 
signalling intermediates (Kolesnick et al., 1998). A signalling intermediate further 
downstream of TNFR is protein kinase C (PKC). PKC reportedly phosphorylates (and 
so inactivates) the secondary MRF myogenin (Sabourin et al., 2000; Zhou et al., 1994). 
 
As TNFα is implicated in a wide array of cellular processes of both beneficial and 
detrimental consequence to the cell, it could be well understood that TNFα signalling is 
indeed extremely complex, and well beyond the scope of this thesis. A more 
comprehensive description of TNFα signalling was excellently reviewed by MacEwan 
(MacEwan, 2002). 
 
1.8 Molecular mechanisms governing myogenesis  
Myogenesis is a multi-step process that involves the activation of satellite cells, 
expansion of the myogenic pool capable of donating myonuclei, the expression of 
muscle specific markers such as the MRFs, exit from the cell cycle, differentiation into 
myocytes and subsequent fusion into myotubes (Cabane et al., 2004; Cabane et al., 
2003; Langen et al., 2002; Layne et al., 1999; Lee et al., 2002). The myogenic 
transcription factors of the MRF and MEF2 families of transcription factors (described 
previously) regulate the expression of vital muscle-specific genes such as myosin 
heavy and light chains and muscle creatine kinase (Cabane et al., 2003). Extracellular 
signals largely contribute to the decision of the cell to differentiate or not. It has been 
noted that when extracellular signals favour myogenesis instead of mitogenesis, 
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myoblasts undergo cell cycle arrest at the early stage of differentiation. Furthermore, 
induction of cell cycle inhibitors such as p21 and p57, together with myogenin, 
prevents cells from re-entering the cell division cycle (Lee et al., 2002). The 
intracellular pathways regulating the initiation of myogenesis and the muscle specific 
transcription factors have not been fully identified. The extracellular regulated kinase 
(ERK) and p38 mitogen activated protein kinase (p38 MAPK) from the mitogen 
activated protein kinase (MAPK) family (Lee et al., 2002); together with the 
IGF/phosphatidylinositol-3-kinase (PI3K) pathway have all been implicated in 
myogenesis (Cabane et al., 2004; Wu et al., 2000). The MAPKs are indeed important 
components of intracellular pathways relaying extracellular signals to transcription 
factors in the nucleus (Lavoie et al., 1996; Ono et al., 2000; Wu et al., 2000). The 
MAPK pathway is constituted of a series of kinase activation events, initiated at the 
plasma membrane and culminates in the nucleus with the phosphorylation of nuclear 
transcription factors. 
 
At least three MAPK families have been identified namely the extracellular signal-
regulated kinases (ERKs), the c-jun NH3-terminal kinases (JNK)/stress activated 
protein kinase (SAPK), and the p38 MAPK family (Clark et al., 2003; Jones et al., 
2005; Wu et al., 2000). Each of the MAPK pathways are ordered as parallel signalling 
cascades (Figure 1.4) in which MAPK kinase kinases (MAPKKK) phosphorylate dual 
specificity MAPK kinase (MAPKK or MKK), which in turn phosphorylate both 
threonine and tyrosine residues and finally activating the MAPK of the pathway (Clark 
et al., 2003; Ono et al., 2000). ERKs are activated by MEK1 and -2, JNK by MKK 4 
and -7, and p38 by MKK 3 and -6 (Clark et al., 2003; Ip et al., 1998; Robinson et al., 
 25
1997). Whilst ERK is activated by mitogenic signals, p38 and JNK are activated by 
proinflammatory and stressful stimuli (Clark et al., 2003). 
 
As mentioned previously, ERK and p38 MAPK, have been implicated in the regulation 
of the myogenic program (Wu et al., 2000). 
 
1.8.1 ERK involvement in myogenesis  
The ubiquitously expressed ERKs are strongly activated by mitogenic signals (Cabane 
et al., 2003; Lavoie et al., 1996). Despite being implicated in myogenesis, their exact 
involvement is controversial, with some reports deeming the ERK pathway necessary 
for muscle differentiation whilst others hold that an inhibition of ERK activity 
promotes myogenesis (Lee et al., 2002; Wu et al., 2000). ERK appears to play a 
biphasic role in myogenesis where its inhibition during the early phases of myoblast 
differentiation, and a subsequent increase in activity at the late stages of differentiation 
is required for normal myogenesis (Wu et al., 2000). 
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Figure 1.4 Schematic illustration of the parallel signaling cascade leading to MAPK 
activation. 
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1.8.2 p38 MAPK as a modulator of myogenesis 
Four isoforms of the p38 MAPK family have been identified: p38 MAPKα, -β, -γ, and 
-δ. The p38α and p38β isoforms are ubiquitously expressed, whilst p38γ is 
predominantly expressed in skeletal muscle (Enslen et al., 2000; Ono et al., 2000). 
Induction of differentiation by serum removal is a common method for studying 
myogenesis in vitro (Wu et al., 2000) (see section on “studying skeletal muscle 
differentiation in vitro”). In a study conducted by Wu (Wu et al., 2000), serum removal 
leads to the induction of p38 activity in C2C12 myoblasts within 1 day, and continues 
to increase for three days, correlating with the time around which myotubes become 
visible. Sustained p38 activity therefore appeared to be part of the muscle 
differentiation pathway, distinct from the pathways stimulated by cytokines, and stress 
(Wu et al., 2000). p38 was found to be functionally linked to muscle differentiation as 
its activation preceded accumulation of myogenin and MyoD (Wu et al., 2000). 
 
Recent studies with kinase inhibitors such as SB-203580 (inhibits p38α, and -β 
isoforms), recent studies confirm that p38 MAPK plays an important role in muscle 
differentiation (Cabane et al., 2003). Interestingly, such inhibition led to proliferation, 
as opposed to differentiation of H9c2 cardiac myoblasts in differentiation medium (Lee 
et al., 2002). In a study conducted by Cabane et al, (Cabane et al., 2003) for example, it 
was shown that inhibition of p38 blocks the expression of both early (MyoD, p21, and 
p27) and late (MHC, and myosin light chain isoform 3F) markers of differentiation. 
Furthermore, an inability to form myotubes was evidenced in cultures treated with the 
p38 inhibitor SB-203580. It was concluded from the aforementioned study that a 
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functional p38 MAPK pathway is required for both the induction and completion of 
differentiation (Cabane et al., 2003).  
 
Interestingly, the role of p38α/β in vivo appears to be the opposite of that found in cell 
lines. A study by Weston (Weston et al., 2003) indicated that in the context of the 
developing limb, myogenesis was significantly enhanced following p38α/β inhibition. 
The study further highlighted the importance of assessing myogenesis in the presence 
of non-myogenic factors as well (Weston et al., 2003). Further research is required to 
elucidate the current disparities in the literature. 
 
Many effects of p38 are mediated by its substrate MAPK activated protein kinase 
(MAPKAPK-2) (Clark et al., 2003; Ono et al., 2000). Activated MAPKAPK-2 
phosphorylates further downstream substrates such as heat shock protein 27 (HSP27) 
(Stokoe et al., 1992), serum response factor (SRF) (Heidenreich et al., 1999), and 
various transcription factors including ATF-2, p53, MEF2A, and MEF2C (Ono et al., 
2000). 
 
A major function of p38MAPK pathway is the regulation of pro inflammatory gene 
expression in cells of the immune system. p38MAPK is, as such, identified as a 
potential therapeutic target in inflammatory disease (Ono et al., 2000). 
 
1.8.3 The phosphoinositide-3-kinase (PI3-kinase) pathway 
The PI3-kinase pathway is activated greatly by IGF, a factor released following muscle 
damage (Cabane et al., 2004; Wu et al., 2000). The IGF-PI3-kinase pathway appears to 
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act in parallel with the p38 MAPK pathway, both these pathways being vital for 
myogenesis (Cabane et al., 2004; Wu et al., 2000). Interestingly, Akt (also known as 
protein kinase B/PKB), a key downstream substrate to PI3K, was found to be a further 
downstream effector of p38 (Cabane et al., 2004). An interaction between the IGF-PI3-
kinase- and p38 MAPKs pathways was therefore suggested (Cabane et al., 2004). 
 
 30
1.9 Differential effects of TNFα on muscle 
A wide variety of studies on the effects of TNFα on the skeletal muscle differentiation 
program are found in the literature. The emerging picture is that TNFα has an effect on 
all aspects of myogenesis from activation and proliferation of satellite cells to cell cycle 
exit, expression of markers of differentiation such as myogenin and MHC, to myotube 
formation (Guttridge et al., 2000; Langen et al., 2001; Langen et al., 2004; Layne et 
al., 1999; Li, 2003; Li et al., 2000; Li et al., 2001b; Li et al., 1998). 
 
Most reports in the literature classify TNFα as an agent that negatively regulates 
myogenesis. However, an interesting and relevant finding by Li & Schwartz (Li et al., 
2001b) indicates that TNFα mRNA level and activity is up regulated for up to 48 hours 
in C2C12 myoblasts responding to serum restriction. What is more, the endogenous 
TNFα stimulated “muscle gene expression” as measured by MHC expression. The 
aforementioned effect was abolished by the introduction of TNFα-neutralizing 
antibodies (Li et al., 2001b). It was concluded from the aforementioned study that 
TNFα is required for the normal differentiation program in muscle (Li et al., 2001b). 
The findings from the aforementioned study further substantiate the consideration that 
TNFα is a relevant factor in muscle regeneration. 
 
Studies of cultures treated with exogenous TNFα have mostly contrasting outcomes on 
differentiation. 
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1.9.1 Anabolic effects of TNFα 
In a study by Li (Li, 2003), TNFα was shown to exert a mitogenic effect on satellite 
cells. Proliferating primary myoblasts incubated with recombinant TNFα at 
concentrations ranging from 2 to 6ng/ml for 24h, showed a significantly progressive 
increase in DNA content (indicating enhanced proliferation). Moreover, TNFα (6ng/ml, 
for a 16h incubation period) increased the number of proliferating myoblasts 
incorporating BrdU, suggesting increased DNA synthesis as a result of faster cell cycle 
progression from G1 to S phase (Li, 2003). The study further illustrated that TNFα is 
capable of activating quiescent satellite cells to enter the cell cycle. Li therefore 
demonstrated that TNFα not only enhanced satellite cell proliferation once initiated (so 
called progression factor) (Li, 2003), but that it also stimulated normally quiescent 
satellite cells to proliferate (so called competence factor) (Li, 2003). 
 
1.9.2 Catabolic effects of TNFα 
TNFα’s involvement in myogenesis has only recently been recognized. The cytokine 
was first identified as a factor reducing tumour size whilst causing muscle wasting in 
tumour-bearing rats (Warren et al., 2002) and has long been associated with cachectic 
muscle wasting (Li et al., 2001b), a chronic wasting disease characterised by 
disproportionate skeletal muscle loss seen in many chronic disease states (Langen et 
al., 2002; Langen et al., 2004). TNFα was in fact once referred to as cachectin in 
acknowledgment of its catabolic actions (Li et al., 2000; Li et al., 2001b). Muscle 
wasting is commonly found in individuals suffering chronic conditions such as cancer, 
acquired immunodeficiency syndrome (AIDS), chronic obstructive pulmonary disease 
(COPD), and chronic heart failure (Anker et al., 1997; Guttridge et al., 2000; Schols et 
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al., 1998; Weinroth et al., 1995). The ensuing loss of muscle mass contributes to 
weakness and fatigue in affected individuals (Li et al., 1998). Muscle wasting in the 
aforementioned diseases contributes significantly to morbidity and mortality in affected 
individuals (Langen et al., 2004; Li et al., 2000; Li et al., 1998). Elucidating the 
relevant factors and mechanisms involved in such muscle wasting is therefore of 
clinical relevance. 
 
It is significant that muscle wasting seen in chronic wasting conditions is associated 
with an elevation in circulating inflammatory cytokine levels, particularly TNFα. TNFα 
is, as such, proposed to be a major trigger of the series of catabolic events that 
constitute muscle wasting (Langen et al., 2001; Langen et al., 2004; Li et al., 1998). 
Support for this is evidenced by the diminished muscle mass found in animals treated 
with exogenous TNFα (Buck et al., 1996), or in experimental conditions mimicking 
disease states exhibiting presenting elevated endogenous TNFα levels (Li et al., 
2001a), such as tumour implantation (Tessitore et al., 1993). Muscle wasting is 
manifested as a loss of muscle protein such as myosin heavy chain (MHC), (a major 
myofibrillar protein characteristic of later stages- and terminal differentiation) although 
the mechanisms underlying such catabolism remain unclear. TNFα induces loss of 
muscle specific proteins (like MHC) (Langen et al., 2001; Li et al., 1998) and as such it 
is clearly implicated as a mediator of muscle wasting. 
 
Muscle wasting could be considered as an anabolism-catabolism imbalance: where 
muscle degradation exceeds that of muscle protein synthesis (Langen et al., 2001). 
Such an imbalance was indeed found in the case of experimental models of cancer 
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cachexia (Buck et al., 1996) and sepsis (Vary et al., 1996) where inflammatory 
mediators were proposed to trigger the wasting events. Little is known about the 
proposed direct effects of TNFα on muscle (Li et al., 1998). Earlier studies (Goodman, 
1991) explored the catabolic actions of TNFα in vivo, subjecting rats to supra-
physiologic concentrations of the cytokine (Garcia-Martinez et al., 1993). Contrary to 
expectations, no significant change in protein breakdown was found in these studies, 
leading researchers to believe that a direct role for TNFα in muscle 
breakdown/proteolysis does not exist (Garcia-Martinez et al., 1993; Goodman, 1991). 
Investigators have since also exposed excised skeletal muscle to supra-physiologic 
concentrations of TNFα for periods as short as 3h, finding no significant alterations in 
protein breakdown (or amino acid release) (Goodman, 1991; Rofe et al., 1987). 
Findings from such studies lead researchers to conclude that TNFα’s role in muscle 
breakdown is not a direct one. Cell culture protocols have become a widespread means 
of studying inflammatory cytokine effects on skeletal muscle. However, studying 
skeletal muscle in vitro/ in culture does have its shortcomings. An important 
consideration is that the environment the cells are grown in are devoid of many of the 
anabolic (and other) factors found in a whole body system that could affect the 
outcome of the body’s response to the factor being investigated. Cell culture models do 
however remain a valuable tool for studying satellite cell differentiation in vitro. 
 
1.9.3 Effect of TNFα on C2C12 cells 
Various researchers have assessed the direct effects of inflammatory cytokines 
including TNFα on differentiated C2C12 myotubes. It was found in one such study that 
there was a concentration dependent decrease in MHC protein in myotubes treated with 
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TNFα (1-10ng/ml) every 24h (Li et al., 1998). The same research group confirmed 
their cell culture based findings, published in 2001, when they again found a significant 
concentration dependent decrease in MHC protein in TNFα treated C2C12 myotubes 
(Li et al., 2001b). However, this in contrast with the studies investigating the direct 
effects of TNFα on muscle described above. 
 
An experiment by Langen and his group (Langen et al., 2001) compared the effects of 
pro-inflammatory cytokines (on C2C12 cells), both during myogenic differentiation 
and on already differentiated myotubes. After treating differentiated myotubes with 
TNFα at doses ranging from 1-50 ng/ml for 72 hours, the overall effects of TNFα on 
the myotubes were insignificant and occurred only at the very highest dose (50ng/ml) 
supplemented (Langen et al., 2001). A dose dependent increase in total protein content 
was in actual fact found, thereby excluding the possibility that the cytokine exerted any 
direct catabolic effects on the myotubes, - a finding contradictory to that of Li et al 
1998, 2001 (discussed above). Allowing myoblasts to differentiate in the presence of 
TNFα on the other hand, did have a significant outcome on their subsequent 
differentiation (Langen et al., 2001). C2C12 myoblasts treated with varying doses of 
TNFα (0.1-10 ng/ml) for 72h, showed a dose dependent suppression of differentiation 
markers myogenin and MHC (Langen et al., 2001). Moreover, addition of the cytokine 
(particularly the 1ng/ml and 10ng/ml doses) prevented the formation of myotubes. 
 
In a further study by Langen et al (Langen et al., 2004) C2C12 cells were again 
allowed to differentiate in the presence of TNFα (10ng/ml) for either 24 or 48 hours. 
The treated cells exhibited attenuated muscle specific gene mRNA levels (Langen et 
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al., 2004). The up regulation of muscle specific gene transcripts during normal 
differentiation was markedly attenuated in the cultures differentiated in the presence of 
TNFα (Langen et al., 2004). Both MyoD gene transcripts and protein levels were 
significantly decreased by 72h post serum-restriction in the TNFα treated cultures 
(Langen et al., 2004). The outcome of a further experiment in the same study indicated 
that TNFα prevented cell cycle exit of myoblasts through sustained expression of the 
cyclin D1 protein. TNFα’s apparent effect on the differentiation of myoblasts would 
explain part of its involvement in muscle pathology. 
 
The muscle differentiation program of C2C12 cells allowed to differentiate in the 
presence of 20ng/ml of TNFα for 72 hours was inhibited, as evidenced by reduced 
expression of the myogenin and MyoD proteins (Guttridge et al., 2000). TNFα is 
known to be an effective activator of NFĸB (Guttridge et al., 2000; Li et al., 2001a). 
NFĸB positively regulates cell proliferation by regulating the expression of the cell 
cycle progression factor cyclin D1 (Guttridge et al., 2000). This presents one possible 
mechanism by which TNFα hinders the differentiation program of myoblasts, again 
referring to the mitogenic properties TNFα has in skeletal muscle (Li et al., 2003). 
 
The findings from the above and similar studies draws attention to the consideration 
that inflammatory cytokine involvement in muscle wasting of chronic wasting 
syndromes such as cancer, AIDS, COPD etc may indeed be indirect (as previously 
suggested). By inhibiting the formation of myotubes from satellite cells TNFα reduces 
the regenerative capacity of muscle. 
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1.9.4 TNFα in cytokine-hormone interactions 
An indirect way of promoting protein loss would be to negatively regulate the 
hormones/anabolic growth factors regulating muscle growth such as IGF-I (Broussard 
et al., 2003), insulin, glucagon, thyroid hormone and catecholamines (Layne et al., 
1999; Tessitore et al., 1993) for example. IGF-I is an anabolic factor known to 
stimulate protein synthesis, myofiber hypertrophy and stimulate myogenesis 
(Broussard et al., 2003; Layne et al., 1999; Strle et al., 2004). TNFα obstructs IGF-I 
mediated muscle growth by inhibiting functionally important phosphorylation of major 
docking proteins of the IGF-I receptor, thereby inducing a state of IGF-I receptor 
resistance (Broussard et al., 2003). Low doses of TNFα (0.01 – 1ng/ml) dose-
dependently attenuated IGF-I stimulated protein synthesis (including that of myogenin) 
in C2C12 myoblasts (Broussard et al., 2003). It was shown that ceramide, a 
sphingosine-based lipid second messenger (Strle et al., 2004) is required for 
proinflammatory cytokine attenuation of IGF action (Strle et al., 2004).  
 
Reactive oxygen species (ROS) form part of proinflammatory cytokine signaling (Garg 
et al., 2002). Skeletal myocytes treated with proinflammatory cytokines (including 
TNFα) resulted in the production of ROS and reactive nitrogen species (Williams et al., 
1994). Reactive oxygen intermediates (ROI) are implicated in both pro-survival and 
pro-apoptotic signaling (Garg et al., 2002) and are required for the activation of several 
signalling molecules (of the TNF-stimulated signaling pathway) including NFkB, 
activated protein-1 (AP-1), JNK, MAPK, as well as the induction of apoptosis (Garg et 
al., 2002; Langen et al., 2002). 
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Oxidative stress has, however, also been implicated in muscle wasting (Langen et al., 
2002). Chronically elevated proinflammatory cytokine levels would significantly alter 
the redox state of the cell (through TNFα-induced ROS). ROS may influence several 
signalling pathways (including ERK, JNK, and NFĸB) (Langen et al., 2002) and 
mitochondrial respiration. It could further be directly linked to muscle protein 
breakdown as oxidation of sulfhydryl groups on contractile proteins could lead to 
degradation of contractile proteins, particularly in chronic disease states (Supinski, 
1998). TNFα’s dose- and time dependent effects could perhaps, in part, be ascribed to 
elevated levels of ROS accompanying (chronically) elevated levels of TNFα. 
 
The findings from studies such as the ones described herein, further brings to attention 
the fact that the effects of TNFα are dose- and time dependent. However, an in depth 
characterisation of the dose dependent effects of TNFα on satellite cell differentiation 
is required, to obtain more insight into its mechanisms of action. 
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AIMS OF THE STUDY 
 
The aims of the current thesis were to: 
 
1) Characterise the temporal patterns of expression of the following proteins 
during differentiation of C2C12 cells  
- MyoD, 
- Myogenin, 
- p21, 
- PCNA, and 
- p38 MAPK for the purposes of subsequently 
2) Investigating the differential effects of chronically supplemented low, medium 
      and high doses of TNFα on differentiating satellite cells on the expression of  
      these proteins. 
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1 In vitro model: C2C12 cell cultures 
2.1.1 Culture conditions 
The C2C12 murine skeletal muscle satellite cell line was obtained from the European 
Collection of Cell Cultures (ECACC). Cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) (Highveld Biological (PTY) Ltd, RSA) supplemented with 
10% fetal bovine serum (Highveld Biological (PTY) Ltd, RSA), 2mM L-glutamine 
(Sigma Aldrich), and antibiotics (1% Penicillin/Streptomycin (PenStrep), Highveld 
Biological (PTY) Ltd, RSA) (here on referred to as culture medium). Cells were 
cultured in T75 flasks (75cm2 flasks, Greiner Bio One) until 80% confluent (i.e 
covering 80% of the culture flask surface), at which time cells were split and seeded 
into T25 (25cm2) flasks (at a seeding density of 300 000 cells per T25) in culture 
medium for a further 24 hours. Following the 24 hours, culture medium was replaced 
by differentiation medium: DMEM supplemented with 2% horse serum (Sigma 
Aldrich), 2mM L-glutamine, and antibiotics (as in culture medium above) to initiate 
differentiation. Cultures treated with TNFα received differentiation medium 
supplemented with TNFα (recombinant murine TNFα, Cytolab Ltd, Israel) at either 
low (0.5ng/ml), medium (5ng/ml), or high (10ng/ml) doses (Table 2.1). Fresh 
differentiation medium (vehicle, and in the aforementioned doses) was added every 24 
hours for 7 days. All cells were cultured in an environment of 95% humidity, 20% O2, 
5% CO2 at 37°C, and were handled in sterile laminar flow hoods. 
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Table 2.1. Varying doses of TNFα supplemented to differentiation medium of 
C2C12 cell cultures 
[Stock]  Final dose 
Dose description 
mg/ml ng/ml 
Control  ~ ~ 
Low dose TNFα 1 0.5 
Medium dose TNFα 10 5 
High dose TNFα 20 10 
 
 
2.2 Harvesting and preparing cells for analysis 
Cells were harvested at specific points along the course of their differentiation: at days 
0, 1, 3, 5, 7 (Figure 2.1). Cultures to be harvested were washed with cold Phosphate 
Buffered Saline (PBS) prior to the addition of lysis buffer composed of 2.5 
mMTris/HCl, 1mM EDTA, 1mM EGTA, 250mM sucrose, 50mM NaPPi, 1mM DTT, 
0.1mM PMSF, 1% (v/v) Nonidet P-40, 0.1% (m/v) SDS, 0.5% (v/v) Na Deoxycholate, 
and a cocktail of protease inhibitors. Flasks were incubated on ice for 2-5 minutes 
before adherent cells were scraped from the culture flask, and the whole cell lysates 
were further sonicated before being stored at -80°C for protein determination and 
further analysis Sample protein concentration was determined by the Bradford protein 
determination method (Bradford, 1976). Aliquots of each sample (containing either 20 
or 30μg protein depending on gel lane volume restrictions) were made and stored at -
80°C for analysis by western blotting. 
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Figure 2.1 Schematic representation of the study design. C2C12 cells were treated 
every 24 hours with fresh differentiation medium, or medium supplemented with 
increasing doses of cytokine (see text). * Time points at which cells were harvested for 
western blot analysis. # Time points at which immunohistochemistry was performed. 
 
Days 
0 1 3 5 7
* * * * *
Induction of 
differentiation 
-1 
C2C12 cells 
seeded in T25 
flasks 
* Days cells harvested for western blot analysis 
# Days immunohistochemistry performed 
 
# # 
4 
# 
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2.3 Western blot analysis  
Whole cell lysates were separated on 10% polyacrylamide gels by sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE). A prestained protein marker 
(peqGOLD) was loaded on each gel to verify molecular weight of specific bands. 20 or 
30μg of protein (sample description above) was loaded per lane. Gels were run for 75 
minutes (or until the front moved off the gel), at 130V (constant) and 400mA (Mini 
Protean System, Bio-Rad, Hercules). Following SDS-PAGE, proteins were transferred 
to polyvinylidine fluoride (PVDF) membranes (Immobilon, Millipore, USA) via wet 
transfer (100V (constant), 350mA, 65 minutes). To prevent non-specific binding, 
membranes were blocked in Blotto (5% (w/v) non-fat dried milk powder in Tris 
Buffered Saline-Tween20 (TBS-T, 0.05%)) for 1-2 hours at room temperature. 
Membranes were incubated with primary antibodies (diluted in either Blotto (for Santa-
Cruz antibodies) or TBS-T (for Cell signalling antibodies)) against the desired proteins 
(Table 2.2) at 4°C for (minimum) 24 hours. Following 2 wash steps (TBS-T) of 7.5 
minutes each, membranes were incubated in either anti-rabbit (Amersham Biosciences, 
UK limited, and Dako Cytomation, Denmark) or anti-mouse (Dako Cytomation, 
Denmark) horseradish peroxidase-conjugated secondary antibody for 1-1.5 hours at 
room temperature. Following the incubation period, membranes were washed for a 
further three times, 5 minutes in TBS-T, followed by a final 15 minute wash step in 
TBS. Antibodies were detected with enhanced chemiluminescence (ECL) kit 
(Amersham Biosciences, UK limited), and bands were visualised on x-ray film 
(Hyperfilm, Amersham Biosciences, UK limited). Bands visualised were quantified by 
densitometry with the UN-SCAN-IT© program (Silk Scientific Corporation, Utah, 
USA). 
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Table 2.2. Primary antibodies used in western blot analysis. 
Molecular 
weight   
(kDa) 
Species raised in Manufacturer Dilution 
MyoD 38 rabbit Santa Cruz* 1/100 
Myogenin 43 mouse Santa Cruz* 1/200 
p21 21 mouse Santa Cruz* 1/100 
PCNA 45 mouse Santa Cruz* 1/200 
phospho-p38α/β MAPK 43 rabbit Cell Signaling# 1/500 
Total p38α/β MAPK 43 rabbit Cell Signaling# 1/500 
 
*Santa Cruz, Santa Cruz, CA 
# Cell Signaling, MA, USA  
 
 
2.3.1 Statistical analysis 
Data were expressed as mean ± SEM. Due to the small sample size (n=3-7), non 
parametric tests were conducted. A statistician advised the employment of the Kruskal 
Wallis ANOVA for comparisons between the 4 groups (control and 3 TNFα treated 
groups) at a specific time point. Dunn post hoc analysis was performed if a significant 
difference (p<0.05) was found. When wanting to compare control cultures to only one 
of the treated groups (control vs. high dose TNFα treated cultures for example), a Mann 
Whitney U test was conducted. A Bonferroni type correction was then subsequently 
made whereby only a P-value of p<0.017 was considered significant. All statistical 
analyses were conducted with the aid of Statistica version 7 software. 
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2.4 Immunohistochemistry 
C2C12 cells for staining were cultured in 8 chamber plates (Nunc, NY, USA), and 
induced to differentiate as described previously. Cells at day 1, 4, and 7 of their 
differentiation program were manipulated for immunostaining (See Appendix A for 
schematic representation of immunohistochemistry procedure). Half of the wells served 
as PBS controls to the remainder of the treated wells. Wells were washed once with 
sterile PBS (0.1M, for staining) before fixing with 1:1 methanol-acetone for 10 minutes 
at 4°C, thereafter allowed to air dry for 20 minutes, and subsequently rinsed with PBS. 
Non-specific binding was blocked by incubating in 5% donkey serum (in PBS) for 20 
minutes at room temperature. The following steps were conducted in a dark and moist 
environment. Primary antibodies (in PBS, see Table 2.3 for dilutions and descriptions) 
were added to wells of the 8 chamber plate (excluding PBS control wells) for 90 
minutes at room temperature.  
 
 Table 2.3. Primary antibodies used for immunostaining of C2C12 cells. 
Species  
  
raised in  
Manufacturer Dilution 
MyoD rabbit Santa Cruz 1/50 
Myogenin mouse Santa Cruz 1/50 
phospho-p38α/β MAPK rabbit Cell Signaling 1/50 
 
 
Wells were rinsed with PBS following the incubation period, where after secondary 
antibodies were added to all wells for a further 30 min (see table 2.4 for dilutions). The 
nuclear marker Hoechst (1/200) was then added to all wells for a 10 minute incubation 
period. Wells were again washed thoroughly with PBS, and a drop of mounting fluid 
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added to each well. Images of stained cells were captured immediately or within two 
weeks of staining. Images were captured on an Olympus IX81 microscope fitted with 
CellR® software. 
 
 Table 2.4. Secondary antibodies used in immunostaining of C2C12 cells. 
Fluorescent marker Secondary 
antibody conjugated to antibody 
Manufacturer Dilution 
Donkey anti-
mouse 
Fluorescein Streptavidin 
(FITC) Invitrogen, CA, USA 1/200 
Donkey anti-
rabbit 
Fluorescein Streptavidin 
(FITC) Invitrogen, CA, USA 1/200 
Horse anti-mouse Texas Red Streptavidin Jackson ImmunoResearch  1/200 
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CHAPTER 3: RESULTS 
 
3.1 Protein expression profiles in a differentiation model 
Satellite cell differentiation over time was visualised by phase contrast microscopy 
(Figure 3.1). Following the induction of differentiation, myoblast cytoplasm becomes 
more profuse. Cell extensions become evident by day 3, and myotube formation is 
prominent by day 5. By day 7 the majority of cells have differentiated and some degree 
of myotube fusion has taken place. 
 
The temporal cellular protein expression profiles of various markers in differentiating 
C2C12 cells were first investigated in our model (Figures 3.2 – 3.5).  
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Figure 3.1 Differentiation of C2C12 cells: Day 1 (A), Day 3 (B), Day 5 (C), Day 7 (D). 
Phase contrast images were taken with (A, C and D), or without (B) a green filter. 
Photographs were taken using a 20X objective. 
 
 
A B 
C D 
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3.1.1 MyoD and Myogenin 
The MRFs MyoD and Myogenin are widely used as markers of differentiation. Their 
protein expression patterns during satellite cell differentiation were, as such, assessed 
as part of our study. 
 
The primary MRF, MyoD (Figure 3.2A) is required for the commitment of myoblasts 
to differentiation. As expected, a dramatic increase in MyoD protein was evidenced 
between baseline (day 0) and day 1 (i.e. over the first 24 hours following the 
differentiation stimulus). MyoD protein expression was reduced between days 1 and 3, 
and sustained between days 3 and 5. Interestingly, MyoD protein displayed a biphasic 
mode of expression, as an elevation in MyoD protein was again seen between days 5 
and 7 of the differentiation program in our model. 
 
Myogenin, as a secondary MRF, is characterised as a marker of middle to terminally 
differentiated myotubes. As such, no detectable levels of myogenin expression were 
found at baseline (Figure 3.2B). Myogenin protein expression increased steadily up to 
day 5 in our model, prior to a drop in myogenin between days 5 and 7. 
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Figure 3.2 MyoD (A) and myogenin (B) protein expression profile in differentiating 
C2C12 cells. Error bars indicate SEM for 3 independent experiments. 
A 
B 
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3.1.2 p21 and PCNA, markers of the cell cycle. 
As the cell cycle (and its subsequent inhibition) is such an important component of the 
differentiation pathway, we further went on to assess the protein expression of p21 and 
PCNA. This allowed us to provide a more complete characterisation of the C2C12 cell 
differentiation process and the subsequent effects of TNFα thereon (see 3.2 below). 
 
p21 expression in our model (Figure 3.3A) showed a steady rise for three days 
following the induction of differentiation at day 0. There after, p21 protein leveled off 
and remained elevated up to day 7, the last time point for measurement in our study.  
 
PCNA was assessed as a marker of proliferation in the present study. No marked 
changes in the protein expression profile of PCNA were detected for the first 5 days 
following the induction of differentiation (Figure 3.3B). A slight elevation in PCNA 
expression was however maintained for three days following the differentiation 
stimulus, followed by a return to (approximately) basal level at day 5. A considerable 
increase in PCNA expression between days 5 and 7 was detected in our model. 
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Figure 3.3 Protein expression profile of p21 (A), PCNA (B) in differentiating C2C12 
cells. Error bars indicate SEM for 3 independent experiments. 
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3.1.3 p38 MAPK 
p38 MAPK as integral signaling molecule in myogenesis was assessed in this study. 
Total p38 remained relatively constant over time. A marked increase in p38α/β 
phosphorylation was detected over the first 24 hours following the differentiation 
stimulus (Figure 3.4). A drop in such phosphorylation followed between days 1 and 5. 
p38 MAPK in our model exhibited a biphasic pattern of phosphorylation as a rise in 
phospho-p38 again occurred between days 5 and 7 of the differentiation program. The 
phospho-p38 pattern of expression described here is analogous to that of MyoD. 
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Figure 3.4 Ratio of phosphorylated- to total p38α/β in differentiating C2C12 cells. 
Error bars indicate SEM for 3 independent experiments. 
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3.2 Dose-dependent effects of TNFα on differentiating satellite cells 
The graphs presented from hereon forth illustrate the dose-dependent effects of 
chronically supplemented TNFα on differentiating satellite cells. Protein expression 
levels (as determined by western blot analysis) are expressed relative to each harvest 
day control, such that control values equal 1 (or otherwise stated 100%) and the dose-
dependent effects are thereby visualized relative to the control value. 
 
3.2.1 MyoD expression: cells commited to myogenic differentiation 
Compared to controls, all TNFα treated cultures showed a trend towards elevated 
MyoD protein at day 1 (Figure 3.5). Low and medium dose cytokine treated cultures 
reached near significance compared to controls (Mann Whitney U test control vs. low 
p=0.036; control vs. medium p=0.036). With continued TNFα supplementation 
however, MyoD protein seemed to decrease in cytokine treated cells relative to controls 
at days 3 and 5. A slight (though statistically insignificant) elevation in MyoD protein 
in low dose (0.5ng/ml) TNFα treated cultures compared to controls seems possible for 
day 7, whereas medium- (5ng/ml), and high dose (10ng/ml) treated cultures showed a 
trend towards decreased MyoD protein, similar to that seen at days 3 and 5. 
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Figure 3.5 Schematic representation of MyoD protein expression relative to harvest 
day control levels (Mean ± SEM, n=3) (A). Representative western blot (B). 
 
Myoblasts were allowed to differentiate in the presence or absence of TNFα at low (0.5ng/ml), 
medium (5ng/ml), or high (10ng/ml) doses for 7 days. Cultures were treated every 24 hours 
where fresh differentiation medium (controls) or medium supplemented with TNFα was 
administered. Whole cell lysates were analysed by western blotting techniques. 
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3.2.2 Myogenin as a marker of middle to terminally differentiated myotubes 
As a marker of middle to terminally differentiated myotubes, myogenin was assessed 
from day 3 onwards (Figure 3.6). In the present study, supplementation with a high 
dose of TNFα negatively regulated myogenin expression more so than supplementation 
with any of the other doses. Although statistically insignificant at days 3 and 5, a trend 
towards decreased myogenin expression in high dose treated cultures (relative to 
controls) was evident at the aforementioned timepoints. A dose dependent decrease in 
myogenin protein in all cytokine treated cultures became evident at day 7, where high 
dose TNFα treated cultures exhibited significantly less myogenin protein compared to 
controls (Mann Whitney U test, control vs. high p<0.017). 
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Figure 3.6 Schematic representation of myogenin expression relative to harvest day 
control levels (Mean ± SEM, day 3, 5 n=7; day 7 n=4) (A). Statistical analysis: Mann 
Whitney U test control vs. high dose, # p < 0.017. Representative western blot (B). 
 
Myoblasts were allowed to differentiate in the presence or absence of TNFα at low (0.5ng/ml), 
medium (5ng/ml), or high (10ng/ml) doses for 7 days. Cultures were treated every 24 hours 
where fresh differentiation medium (controls) or medium supplemented with TNFα was 
administered. Whole cell lysates were analysed by standard western blotting techniques. 
#
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3.2.3 Cell cycle inhibition: promotion of differentiation by p21 
The pattern of p21 protein expression in treated cells was similar to that of MyoD: At 
day 1, TNFα treated cultures displayed elevated levels of p21 protein compared to 
controls (Figure 3.7). Low and medium dose cytokine treated cultures reached near 
significance when compared to controls (Mann Whitney U test control vs. low 
p=0.036; control vs. medium p=0.036). With continued TNFα supplementation, this 
seemingly positive effect on differentiating myoblasts was reversed. At day 3, a trend 
existed for TNFα treated cultures to show a slight decrease in p21 protein compared to 
controls. A dose dependent decrease in p21 was observed at day 5 in TNFα treated 
cultures (p<0.05, Kruskal Wallis ANOVA). Post hoc analysis indicated that high dose 
treated cultures showed significantly less p21, and therefore cell cycle exit, compared 
to control cultures (Dunn post hoc analysis). Similar to the trend of MyoD expression 
in treated cells at day 7: p21 expression was slightly elevated in low dose cytokine 
treated cultures, but reduced in medium- and high dose treated cultures relative to 
controls. 
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Figure 3.7 Schematic representation of p21 expression relative to harvest day control 
levels (Mean ± SEM, day 1, 3, 5 n=3; day7 n=5) (A). Statistical analysis: Kruskal 
Wallis ANOVA, *p<0.05, # p<0.05 (Dunn post hoc test). Representative western blot 
(B). 
 
Myoblasts were allowed to differentiate in the presence or absence of TNFα at low (0.5ng/ml), 
medium (5ng/ml), or high (10ng/ml) doses for 7 days. Cultures were treated every 24 hours 
where fresh differentiation medium (controls) or medium supplemented with TNFα was 
administered. Whole cell lysates were analysed by standard western blotting techniques. 
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3.2.4 PCNA 
Proliferation of C2C12 cells in our model was assessed by PCNA expression in 
differentiating satellite cells (Figure 3.8) 
 
No significant difference in PCNA protein existed between control and TNFα treated 
cultures (Figure 3.8). A slight (statistically insignificant) trend for increased PCNA 
protein with increasing doses of cytokine does however, seem possible at day 5. PCNA 
was not assessed at day 1.  
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Figure 3.8 Schematic representation of PCNA expression relative to harvest day 
control levels (Mean ± SEM, n=3) (A). Representative western blot (B). 
 
Myoblasts were allowed to differentiate in the presence or absence of TNFα at low (0.5ng/ml), 
medium (5ng/ml), or high (10ng/ml) doses for 7 days. Cultures were treated every 24 hours 
where fresh differentiation medium (controls) or medium supplemented with TNFα was 
administered. Whole cell lysates were analysed by standard western blotting techniques. 
  
A 
B 
 62
3.2.5 p38 MAPK.  
The differential effects of TNFα on an integral pro-differentiation signalling pathway 
were assessed at the hand of p38α/β MAPK (Figure 3.9). The addition of TNFα did not 
significantly alter the phosphorylation of p38 at day 1 (except for a slight statistically 
insignificant elevation with high dose TNFα supplementation). With continued TNFα 
supplementation however, a dose dependent decrease in phospho-p38 followed at day 3 
of the differentiation program was observed (Kruskal Wallis ANOVA p<0.05). 
Although less phospho-p38 was found in all cytokine treated cultures at day 5, this 
finding was not significant. A reversal in the pattern seen at days 3 and 5 was evident at 
day 7, as there was a dose dependent increase in phospho-p38 at this time point 
(Kruskal Wallis ANOVA p<0.05). Post hoc analysis indicated that high dose treated 
cultures had significantly higher p38 phosphorylation compared to controls. 
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Figure 3.9 Schematic representation of the ratio of phospho-p38α/β relative to harvest 
day control levels (Mean ± SEM, day 1, n=3 day 7, n=4) (A). Statistical analysis: 
Kruskal Wallis ANOVA *p<0.05, # p<0.05 (Dunn post hoc test). Representative 
western blot (B). Tp38 = representative total p38 blot. 
 
Myoblasts were allowed to differentiate in the presence or absence of TNFα at low (0.5ng/ml), 
medium (5ng/ml), or high (10ng/ml) doses for 7 days. Cultures were treated every 24 hours 
where fresh differentiation medium (controls) or medium supplemented with TNFα was 
administered. Whole cell lysates were analysed by standard western blotting techniques. 
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3.3 Immunohistochemistry 
A subsequent set of experiments were conducted to visualise certain markers at days 1, 
4, and 7. 
 
Day 1 cells were stained for MyoD (Figure 3.10). A trend for the movement away from 
a diffuse cytosolic staining to a more nuclear staining of immunoreactive MyoD protein 
with increasing dose of TNFα was visualised (Figure 3.10 A-D). Otherwise stated, it 
appears that a dose dependent nuclear localisation of immunoreactive MyoD was 
evident at day1. 
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Figure 3.10 MyoD staining. Immunohistochemistry of day 1 control (A & E), low (B 
& F), medium (C & G), and high dose (D & H) TNFα treated C2C12 cultures. The left 
hand panel (A-D) shows cells stained for MyoD (FITC, green). The right hand panel 
(E-H) shows merged signals, MyoD (FITC), and Hoechst (stains all nuclei blue). White 
arrows indicate points of interest. Images are at a 60X magnification.  
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Day 4 cells were stained for MyoD (Figure 3.11) and myogenin (Figure 3.12). Merged 
signals of both markers plus the nuclear stain Hoechst are depicted in Figure 3.13. 
 
Cells treated with a high dose of TNFα (Figure 3.11B) displayed a reduced amount of 
immunoreactive MyoD protein (particularly in the nucleus) when compared to control 
cells (Figure 3.11A) at day 4. Please note that where the secondary antibody to MyoD 
was FITC linked (green) for day 1 staining, the secondary antibody to MyoD at day 4 
was Texas red linked, hence the incontinuity in MyoD immunofluorescence. 
 
Less immunoreactive myogenin protein was detected in high dose treated cells (Figure 
3.12 B) compared to controls (Figure 3.12 A). 
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Figure 3.11 MyoD staining. Immunohistochemistry of day 4 control- (A & C) and high 
dose (B & D) TNFα treated C2C12 cultures. The left panel (A & B) shows cells stained 
for MyoD (Texas red). The right panel (C & D) shows merged signals, MyoD (Texas 
red), and Hoechst (stains all nuclei blue). White arrows indicate points of interest. 
Images are at a 60X magnification. 
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Figure 3.12 Myogenin staining. Immunohistochemistry of day 4 control- (A & C) and 
high dose (B & D) TNFα treated C2C12 cultures. The left panel (A & B) shows cells 
stained for myogenin (FITC, green). The right panel (C & D) shows merged signals, 
myogenin (FITC), and Hoechst (stains all nuclei blue). White arrows indicate points of 
interest. Images are at a 60X magnification. 
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Figure 3.13 Immunohistochemistry of day 4 control (A) and high dose (B) TNFα 
treated C2C12 cultures. Merged signals of MyoD (Figure 3.11), myogenin (Figure 
3.12) and Hoechst (stains all nuclei blue) are shown. Images are at a 60X 
magnification. 
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Cells at day 7 were stained for myogenin (Figure 3.14) and phospho-p38α/β (Figure 
3.15). Merged signals for both markers plus the nuclear stain Hoecsht are depicted in 
Figure 3.16. 
 
Diffuse cytosolic staining of myogenin was visualised in high dose TNFα treated cells 
(Figure 3.14D). In contrast, notably more immunoreactive myogenin protein was 
localised to the nucleus in control cells (Figure 3.14A). Please note that where the 
secondary antibody to myogenin was FITC linked (green) for day 4 staining, the 
secondary antibody to myogenin at day 7 was Texas red linked, hence the incontinuity 
in myogenin immunofluorescence. 
 
Immunoreactive phospho-p38α/β was localised to the nucleus at day 7 in all cultures 
(Figure 3.15). 
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Figure 3.14 Myogenin staining. Immunohistochemistry of day 7 control (A & E), low 
(B & F), medium (C & G), and high dose (D & H) TNFα treated C2C12 cultures. The 
left panel (A-D) shows cells stained for myogenin (Texas red). The right panel (E-H) 
shows merged signals, myogenin (Texas Red), and Hoechst (stains all nuclei blue). 
White arrows indicate points of interest. Images are at a 60X magnification. 
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Figure 3.15 phopsho-p38α/β staining. Immunohistochemistry of day 7 control (A & 
E), low (B & F), medium (C & G), and high dose (D & H) TNFα treated C2C12 
cultures. The left panel (A-D) shows cells stained for phospho-p38α/β (FITC, green). 
The right panel (E-H) shows merged signals, phospho-p38α/β (FITC), and Hoechst 
(stains all nuclei blue). Images are at a 60X magnification. 
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Figure 3.16 Immunohistochemistry of day 7 control, low, medium and high dose (A-
D) TNFα treated C2C12 cultures. Merged signals of myogenin (Figure 3.14), phospho-
p38α/β (Figure 3.15) and Hoechst (stains all nuclei blue) are shown. Images are at a 
60X magnification. 
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CHAPTER 4: DISCUSSION 
 
TNFα has long been implicated in muscle wasting disorders, and was initially referred 
to as cachectin in acknowledgement of its catabolic actions (Li et al., 2000; Li et al., 
2001b). However, a physiological role for this pleiotropic cytokine in skeletal muscle 
regeneration has since been identified (Collins et al., 2001; Li, 2003; Li et al., 2001b; 
Warren et al., 2002). It has become evident that the inflammatory response to muscle 
injury is functionally beneficial (Jarvinen et al., 2005; Tidball, 2005). Following 
muscle damage, soluble factors released from infiltrating immune cells activate and 
chemotactically attract satellite cells to the injured area (as discussed in more detail in 
chapter 1). TNFα is, as such, released from infiltrating macrophages (Collins et al., 
2001; Tidball, 2005), as well as by injured muscle fibers (Collins et al., 2001; Li, 
2003), thereby conferring a relevant role for TNFα in skeletal muscle regeneration. 
 
Much research on the effects of TNFα on satellite cell differentiation has been 
conducted in recent years. The outcomes of such research have been contrasting, 
suggesting both positive and negative outcomes. This can greatly be ascribed to 
different cell lines/models studied, employment of myoblasts vs. myotubes, varying 
doses of TNFα administered, and the duration of TNFα supplementation. It is therefore 
difficult to obtain a clear picture of it’s mechanisms of action as all models slightly 
differ.  
 
We therefore aimed at providing a comprehensive assessment of the effects of 
increasing doses of chronically supplemented TNFα on differentiating satellite cells. 
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The incorporation of various markers in a single model, allowed us to gain better 
insight into the dose dependent actions of TNFα. The doses of cytokine used in our 
study (0.5-10ng/ml) are physiologically relevant. Concentrations of 1-10ng/ml have 
been reported in the circulations of individuals with chronic inflammatory disease 
(Roubenoff et al., 1992). TNFα levels following injury not associated with chronic 
disease states are dependent on the degree of damage. 
 
Model of satellite cell differentiation 
In the first part of the study we were successful in characterising a model of satellite 
cell differentiation in C2C12 cell cultures: The temporal expression patterns of a 
comprehensive range of markers characterising various phases in the differentiation 
program were investigated. 
 
MyoD and myogenin are often used as markers of differentiation in studies on satellite 
cell differentiation. The aforementioned, as part of the MRF family of transcription 
factors, are necessary for the regulation of the myogenic differentiation process (as 
discussed in detail in chapter 1). 
 
The dramatic increase in MyoD protein seen over the first 24 hours following the 
induction of differentiation was as expected, as MyoD is rapidly up-regulated in cells 
committed to the myogenic differentiation program (Sabourin et al., 2000). In vivo, 
members of the myogenic transcription factor families (MRFs and MEF2 families) that 
regulate myogenesis are only expressed once quiescent satellite cells are activated and 
proliferating. Indeed, the levels of MyoD fluctuate within the cell cycle, peaking in G1 
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phase. However, the myogenic regulatory function of MyoD is repressed in cycling 
cells, and only ‘activated’ when differentiation cues are present (during G1 phase of the 
cell cycle). Following differentiation cues (removal of mitogenic signals), MyoD levels 
are further elevated (Dhawan et al., 2005). This serves to explain the presence of 
MyoD at baseline in our model: Satellite cells in culture are already activated and 
cycling prior to the differentiation stimulus, and thus the basal level of MyoD also in 
our model. Once provided with the differentiation stimulus (serum removal), MyoD 
levels are further elevated, and its activity initiated concurrent with the removal of 
mitogenic stimuli. This underscores the value of the use of synchronised reversibly 
quiescent cultures as a more relevant model to an in vivo population of quiescent 
satellite cells. 
 
The spike in MyoD protein expression at day 1 subsided by day 3, and increased again 
between days 5 and 7. This biphasic response implies that there was an increase in 
myoblasts initiating differentiation at day 7, a time point at which myotube formation 
was prominent. The C2C12 cultures used in this study were not synchronized. 
Therefore, there may be populations of cells within the culture at different stages of the 
cell cycle, some only responsive at later stages of the differentiation program. 
 
The steady increase (up to day 3), and sustained (up to day 5) myogenin protein 
expression in our model is in accordance with the literature (Andres et al., 1996; 
Langen et al., 2001), and indicates that cultures in our model were progressing along 
the differentiation pathway. A drop in myogenin expression was seen by day 7. It 
appears from our model that sustained levels of myogenin are not required for the 
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continuity of satellite cell differentiation through to day 7. Other factors required for 
terminal differentiation and cell fusion such the secondary MRF, MRF4, are likely to 
be up-regulated in the advanced stages of differentiation thereby overseeing the 
completion of the differentiation program. 
 
A steadily increased expression of the cell cycle inhibitor p21 for 3 days following the 
induction of differentiation where after it remained elevated for the remainder of the 
differentiation program was observed in our model. This indicates that the 
differentiating cells in our model steadily discontinue proliferation, exit the cell cycle, 
and commence differentiation. The formation of postmitotic multinucleated myotubes 
is, as such, a characteristic of the terminal differentiation (Andres et al., 1996). One 
mechanism by which MyoD regulates myogenesis is through the promotion of cell 
cycle arrest in a mechanism involving induction of p21 (Song et al., 1998). The marked 
increase in MyoD protein between days 0 and 1 was indeed followed by a steady 
increase in p21 protein in our model. Despite being a potent inducer of p21, MyoD is 
by no means the only inducer of p21. It has been reported that both MyoD and serum 
deprivation are required for induction of p21 (Guo et al., 1995). Furthermore, p21 
activity is proposed to be positively regulated by PI3-Kinase and MAPK (Ostrovsky et 
al., 2003). A balance between various factors, and their temporal relationships, 
ultimately determine the total p21 protein levels in differentiating myoblasts 
(Ostrovsky et al., 2003).  
 
No marked increase in proliferation as measured by PCNA expression was detected 
over the first 5 days in our model with western blot analysis. An increase in PCNA 
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protein was however detected between days 5 and 7. This is contrary to what would be 
expected, particularly in light of the p21 data. The PCNA protein in our model was not 
decreased when p21 (and therefore cell cycle inhibition) was elevated. Data from our 
laboratory suggests that even though levels of PCNA protein are not altered, its 
localisation within a cell may be (E.Schabort, unpublished observation). This would 
indeed make sense, as PCNA is an accessory factor to DNA polymerase (Layne et al., 
1999), and it could only carry out its function once in the nucleus. 
 
Employing various methods, recent publications have clearly identified a requirement 
for p38 MAPK (and specifically the α/β isoforms) in myogenic differentiation, (Cabane 
et al., 2003; Chen et al., 2005; Jones et al., 2005; Wu et al., 2000; Zetser et al., 1999). 
A dramatic increase in phospho-p38 for 24 hours following serum removal was also 
evidenced in our model. This brings to light a very important consideration: the 
assumption that p38, once phosphorylated, is activated. The aforementioned is better 
verified by the assessment of its downstream substrates. p38 MAPK reportedly 
promotes myogenesis through mechanisms involving the induction and transcriptional 
activation of the MEF2 and MyoD families (Cabane et al., 2003; Jones et al., 2005; Wu 
et al., 2000; Zetser et al., 1999). Indeed, the pattern of MyoD protein expression in our 
model mimics that of phospho-p38. Both the aforementioned markers show a decline in 
protein expression between days 1 and 5 prior to an increase again between days 5 and 
7. A requirement for p38 in the expression of both early (MyoD, p21) and late (MHC) 
markers of differentiation, as well as myotube formation and cytoskeletal organization 
has been reported (Cabane et al., 2003). We propose that the biphasic mode of p38 
phosphorylation in our model indeed suggests that the late increase in p38 
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phosphorylation plays a role in the attainment of the differentiation phenotype. p38 has 
been implicated in the control of myogenin and p21 expression as well (Cabane et al., 
2003). Incorporating a p38 inhibitor such as SB-203580 into future studies using our 
protocol would better ascertain such an involvement. 
 
In the first phase of the study, the temporal patterns of expression of various factors 
that work in concert to bring about muscle gene expression, and a post-mitotic state 
characteristic of the differentiation phenotype, were investigated. The characterisation 
of such a control culture differentiation model, allowed us to subsequently investigate 
the effects of TNFα on the model. 
 
Dose-dependent effects of TNFα on differentiating C2C12 cells 
The trend towards increased MyoD protein in day 1 control cultures was even further 
elevated in TNFα treated cultures (all doses). This implies that cultures treated with 
cytokine for 24 hours following the induction of differentiation showed enhanced early 
differentiation. As mentioned in chapter 1, an important consideration is that of a 
positive, relevant role for TNFα in myogenesis. The increased MyoD protein content in 
TNFα treated cultures seen in the present study indicates that TNFα (0.5-10ng/ml) for 
24 hours following the induction of differentiation appeared to enhance the initial 
stages of the differentiation program: the induction of a key primary MRF and thereby 
the commitment of cells to the myogenic lineage, and the induction of muscle specific 
gene transcription. Immunohistochemical analysis of day 1 cultures, illustrated a trend 
for immunoreactive MyoD to move away from a diffuse cytosolic- to a more nuclear 
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staining with increasing dose of TNFα (0.5-10 ng/ml), suggesting a dose dependent 
nuclear localisation of the transcription factor (Figure 3.10). 
 
Our findings are in contrast with a study by Guttridge (Guttridge et al., 2000), who 
observed a decreased MyoD protein content in C2C12 cultures after 24 hours of 
cytokine treatment. However the researchers did administer a 20ng/ml dose of 
cytokine, double the concentration of what is referred to as a high dose in our study. 
The contrasting results could be attributed to the fact that a dose of 20ng/ml is 
considered cytotoxic to cells (Dr. R. Smith, unpublished data).  
 
With continually elevated TNFα supplementation in our study, this seemingly positive 
effect on differentiation was reversed. Cytokine treated cultures displayed a trend 
towards less MyoD protein with increasing doses of cytokine at days 3 and 5. 
Immunohistochemistry of day 4 cultures illustrated less immunoreactive MyoD protein 
in the nuclei of high dose treated cells compared to controls (Figure 3.11). This finding 
is in agreement with other reports by Guttridge (Guttridge et al., 2000) and Langen 
(Langen et al., 2004). Both the aforementioned studies did however only assess MyoD 
protein expression with continued TNFα supplementation up to 72 hours following 
serum withdrawal. To our knowledge, few studies assess biochemical markers of 
differentiation at time points beyond 72 hours following the differentiation stimulus. 
Furthermore, few published studies chronically supplement cultures to differentiate in 
the presence of TNFα for as long as 7 days. Our study provided an assessment of 
markers of differentiation at time points further down the myogenic differentiation 
pathway. The trend towards less MyoD protein in (particularly high dose cytokine 
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treated cells) was carried through till day 7. It therefore appears from our data that 
chronic supplementation of TNFα tends to negatively regulate a key early regulator of 
myogenic differentiation, and even more so with higher doses. 
 
Chronic TNFα supplementation (and particularly the high dose of cytokine) negatively 
regulated the protein expression of myogenin, a secondary MRF, and further marker of 
differentiation. Myogenin expression was only assessed from day 3 onwards in the 
present study. There are however, studies in the literature reporting myogenin 
expression as early as day 1 following serum withdrawal (Guttridge et al., 2000; 
Langen et al., 2004). In such reports, cultures differentiating in the presence of TNFα 
(at between 10- and 20ng/ml) reduced both the protein and mRNA expression of 
myogenin at 24 and 48 hours. This is an interesting consideration in light of the 
possible positive effects 24 hours of TNFα supplementation (even at a 10ng/ml dose) 
seemed to have on early differentiation, as measured by MyoD in the present study. 
With continued TNFα supplementation in our study, our data corresponds to that of the 
aforementioned reports, in that myogenin expression tended to be reduced in TNFα 
treated cultures from day 3 onwards. Indeed, immunohistochemical analysis of day 4 
cells indicated less immunoreactive myogenin protein in high dose treated cells 
compared to controls. The trend towards decreased myogenin protein, in particularly 
high dose TNFα treated cultures compared to controls at days 3 and 5, became 
significant at day 7, where a dose dependent decrease became evident. 
Immunohistochemistry of day 7 cells sufficiently illustrated this finding, as 
immunoreactive myogenin protein in control cells appeared to be concentrated in the 
nucleus, whereas less myogenin protein, stained in a diffuse fashion, was evidenced in 
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high dose treated cells (Figure 3.14). Furthermore, the faint nuclear myogenin staining 
compared to that of control cells illustrates that not only was there less myogenin 
protein, but less of the myogenin protein present in the cell appeared localised to the 
nucleus in high dose cytokine treated cells. This underscores the importance of 
addressing the localisation of proteins within a cell. As a transcription factor concerned 
with the induction of muscle specific genes during the conversion of myoblasts to 
mature myotubes, myogenin can only carry out its function if it is active and at the site 
it is needed, i.e. in the nucleus.  
 
Phosphorylation of MRFs reportedly negatively regulates their activity (Sabourin et al., 
2000). PKC has been shown to phosphorylate myogenin on its DNA binding site, 
thereby preventing its binding to promoter regions of muscle specific genes (Sabourin 
et al., 2000; Zhou et al., 1994). PKC is stimulated through TNFR activation 
(MacEwan, 2002). This presents a possible mechanism through which TNFα 
negatively regulates myogenic differentiation, and warrants further investigation.  
 
Similar results are found in the literature in study designs comparable to the one used in 
our study (Guttridge et al., 2000; Langen et al., 2001; Langen et al., 2004), and in 
designs incorporating the roles and interactions of other factors relevant to myogenesis 
(Layne et al., 1999). To our knowledge, few studies assess biochemical markers of 
differentiation at time points beyond 72 hours following the differentiation stimulus. 
Furthermore, few studies reported in the literature allowed cultures to differentiate in 
the presence of TNFα (at any dose) for as long as 7 days. 
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As discussed previously, cell cycle exit is vital to the attainment of the postmitotic state 
characteristic of differentiated muscle. The assessment of markers of the cell cycle 
provided further insight into the dose-dependent effects of TNFα on differentiating 
satellite cells up to 7 days following the induction of differentiation. 
 
The protein expression of cell cycle inhibitor p21, as a broad specificity inhibitor of 
cdk’s, was investigated in the present study. TNFα supplementation (with all doses 
administered) led to an elevated p21 protein expression compared to controls (a trend 
analogous to that of MyoD) at day 1. This is to be expected as mentioned previously, 
MyoD promotes the induction of p21. At day 3, as with MyoD, p21 protein expression 
in cytokine treated cultures tended to be reduced relative to controls, such that the 
seemingly positive effect TNFα supplementation had on myogenesis during the initial 
24 hours post serum removal was reversed with continued cytokine supplementation. 
The dose dependent decrease in p21 that followed at day 5 indicates that TNFα 
significantly inhibited cell cycle inhibition of myoblasts at this advanced phase of the 
differentiation program. This implies therefore that continually elevated levels of TNFα 
negatively regulate cell cycle exit in a dose dependent fashion, and particularly so with 
high doses (10ng/ml) of cytokine at day 5. Otherwise stated, without cell cycle 
inhibition, continued proliferation will occur and differentiation cannot take place as 
(described in chapter 1) the aforementioned events are mutually exclusive. To our 
knowledge, no other study has assessed the effects of chronic TNFα supplementation 
on p21 mediated cell cycle inhibition in vitro.  
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Interestingly, it has been shown that p21 acts as a direct inhibitor of DNA polymerase 
by binding a subunit of PCNA (Roubenoff et al., 1992), a marker of proliferation in our 
study. With the trend towards dose dependent decrease in p21 in cytokine treated 
cultures (significantly so at day 5), a similar, though inverted, pattern of PCNA protein 
expression would be seen. No significant difference in proliferation as determined by 
PCNA protein concentration resultant of cytokine treatment was, however, detected in 
our study. The dose dependent decrease in p21 at day 5 was accompanied by a slight 
trend towards a dose dependent increase in PCNA protein in TNFα treated cultures 
compared to controls. Although Western blot analysis showed no (significant) 
difference in PCNA protein between groups, an effect of TNFα on proliferation in 
differentiating myoblasts could be masked. As only whole cell lysates were analysed 
by western blotting in our study, PCNA protein both in the cytosol at its final site of 
production, and in the nucleus, where it would be involved with DNA replication, 
would be detected. Immunohistochemistry analysis would provide better insight to the 
localisation of PCNA protein (as discussed previously).  
 
Cyclin D1, an integral part of the cell cycle progression machinery (for cell cycle 
review see (Schafer, 1998) presents an alternative marker of proliferation that could be 
included in future studies and thereby delineate a possible mitogenic role for TNFα in 
myogenesis as suggested by Li (Li, 2003). It has been found that TNFα, through the 
action of NFκB, regulates the expression of cyclin D1, thereby promoting cell cycle 
progression (Guttridge et al., 2000). Alternatively, the MTT assay for cell viability and 
proliferation should be considered in future studies. 
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It is reported that p38 activity, required for myogenic differentiation, is induced by 
serum withdrawal via a pathway independent of that stimulated by cytokines and stress 
(Cabane et al., 2003; Wu et al., 2000). The marked increase in phospho-p38α/β 
between days 0 and 1 in our control cell differentiation model, correspond to such 
reports. Recently, Chen (Chen et al., 2005), conducted a study in cardiotoxin injured, 
TNFα receptor double-knockout mice, which for the first time illustrated the 
importance of TNFα receptors in p38 activation during muscle regeneration. It was 
suggested in the aforementioned report that the elevated levels of TNFα present at the 
initiation of the muscle regeneration process, serve to initiate the regeneration process 
via p38. 
 
From the abovementioned it would be implied that concurrent with TNFα 
supplementation, an increase in phospho-p38, over and above that induced by serum 
withdrawal, would be expected in our treated cultures. Over the first 24 hours post 
serum withdrawal, cultures treated with a high dose of cytokine showed a trend towards 
elevated phospho-p38α/β, while the other cytokine treated cultures did not seem to 
differ from controls. 
 
In the normal physiological process of repair following injury, the concentrations of 
TNFα and growth factors are only elevated during the initial stages of muscle 
regeneration (and satellite cell activation). It is only after the removal of mitogenic 
stimuli has taken place that satellite cells can differentiate into new muscle cells to 
bring about repair (Andres et al., 1996; Dhawan et al., 2005; Wu et al., 2000). Indeed, 
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growth promoting factors (mitogenic stimuli) have been shown to inhibit the actions of 
the MRFs (Dhawan et al., 2005; Hawke et al., 2001; Sabourin et al., 2000). 
 
In the current study, a trend existed for TNFα (0.5-10ng/ml) to positively regulate early 
markers of differentiation (MyoD, p21) after 24 hours of supplementation. Similarly, a 
10ng/ml dose of TNFα after 24 hours of supplementation also fit this trend. With 
continued supplementation however, TNFα tended to negatively regulate markers of 
differentiation. The dose dependent decrease in phospho-p38 at day 3 of differentiation 
further illustrates this. It would appear therefore, that continually elevated levels of 
TNFα negatively affects the phosphorylation of the downstream signalling transducer, 
p38 MAPK. This effect seemed to be upheld till day 5 where all cytokine treated 
cultures still, displayed less p38 phosphorylation compared to controls. 
 
Induction of MyoD expression, is one of the mechanisms through which p38 reportedly 
regulates myogenesis. The dose dependent decreases in MyoD protein, seen with 
continually supplemented TNFα in our study, could therefore be attributed to the 
decreased phosho-p38 detected (at days 3 and 5) in our study. 
 
As mentioned previously, p38 activity is reportedly required for the expression (and 
transcriptional activation) of early and late markers of differentiation (Cabane et al., 
2003). As continually elevated levels of TNFα negatively regulated early- (MyoD), and 
later (myogenin) markers of differentiation, and cell cycle inhibition in our study, we 
propose that these effects are resultant of the decreased phospho-p38 levels in treated 
cells (at days 3 and 5) witnessed in our study. 
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Interestingly, a dose dependent increase in phospho-p38 followed at day 7. It is 
possible that in response to continued TNFα supplementation, a degree of receptor 
desensitisation, or receptor down regulation was occurring, with increasing dose of 
cytokine, after day 1 and up to around day 5. By day 7, it would appear therefore that 
some compensatory mechanism had occurred. This would need further investigation.  
 
It is well known that ROS are generated in cultured skeletal myocytes in response to 
inflammatory cytokine exposure (Li et al., 1999; Williams et al., 1994). ROS are 
proposed to play a role in TNFα mediated cytotoxicity (Goossens et al., 1995). We do 
not consider the doses of TNFα administered (0.5 – 10ng/ml) in our study to be 
cytotoxic. The assessment of caspase activity in future studies would serve to confirm 
this. 
 
Limitations to the study and future recommendations 
The C2C12 cultures used in this study were not synchronised, and a heterogenous 
population of cells were therefore studied. The use of synchronised reversibly quiescent 
cultures would be a more relevant model to an in vivo population of quiescent satellite 
cells. 
 
In the present study, markers of differentiation were studied at protein level only. For a 
more comprehensive picture of the effects of TNFα on differentiating satellite cells, it 
would be useful to consider the events at mRNA level as well. Characterisation of the 
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post-transcriptional and post translational events resultant of TNFα supplementation 
could help better characterise the cytokine’s mode of action.  
 
Various trends exist in our data. By increasing our sample size, some of these trends 
may actually reach statistical significance. 
 
Our protein samples were that of whole cell lysates. As a result, the protein expression 
levels in our samples were only a reflection of that in the entire cell. The growing 
importance of immunohistochemical techniques is becoming increasingly clear, as 
immunohistochemistry analysis illustrated that despite no differences in protein levels 
are found by western blotting, a difference in the localisation of proteins between 
samples may well exist. In future it would be advantageous to separate, for example, 
the cytoplasmic, nuclear, and membrane fractions of samples prior to analysis. 2D gel 
electrophoresis would be valuable as a further analytical tool. 
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CHAPTER 5: SUMMARY AND CONCLUSIONS 
 
The effects of TNFα are reportedly dose- and time dependent. Skeletal muscle is often 
affected by diseases of other organs. Indeed, TNFα is implicated in muscle wasting 
associated with chronic disease states such as cancer and AIDS, where its levels are 
chronically elevated. A physiological role for TNFα in muscle regeneration has also 
been reported. Many reports on the effects of TNFα on satellite cell differentiation in 
vitro are found in the literature. However, all models used for these purposes differ 
with regards to doses administered and duration of cytokine supplementation. Here, we 
provide a comprehensive characterisation of the dose dependent effects of chronically 
supplemented TNFα, on C2C12 cells. This research allows for better insight into the 
mechanisms by which TNFα regulates satellite cell differentiation. Markers of 
differentiation were assessed at both early (day 1), and later (days 3, 5, and 7) time 
points after the induction of differentiation. This allows us to draw conclusions of 
TNFα’s differential effects after acute and chronic supplementation. Otherwise stated, 
this mode of TNFα supplementation allows conclusions of its effects on satellite cell 
differentiation in chronic disease states to be drawn as well. 
 
We show here: TNFα supplementation appears to positively regulate early markers of 
differentiation after 24 hours of supplementation. However, with continually elevated 
levels of TNFα, this positive effect on C2C12 differentiation is reversed. Chronically 
elevated levels of TNFα at low, medium, and high doses negatively regulate markers of 
differentiation in a dose dependent fashion. We propose that these effects are mediated, 
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in part, by the attenuation of phospho-p38 MAPK, a recognised activator of 
myogenesis. 
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Appendix A: Table of satellite cell markers 
  
Table 1.1 List of satellite cell markers adapted and modified from  
            (Hawke et al., 2001) and (Charge et al., 2004). 
  
Molecular 
marker  
           Expression pattern in 
satellite cells    Reference 
CD34 Quiescent (Charge et al., 2004) 
CD56 
 
Syndecan-3 & -4 
 
 
Quiescent, activated and proliferating 
 
Cell surface heparin  
sulphate proteoglycans 
 
(Charge et al., 2004; Hawke et al., 
2001) 
 
(Cornelison et al., 2001) 
MNF Quiescent, activated and proliferating (Garry et al., 1997) 
Pax 7 Quiescent, activated and proliferating (Olguin et al., 2004; Seale et al., 2000b) 
c-met Quiescent, activated and proliferating (Cornelison et al., 1997) 
M-cadherin Quiescent, activated and proliferating (Cornelison et al., 1997) 
VCAM-1 Quiescent, activated and proliferating (Charge et al., 2004; Hawke et al., 2001) 
Desmin Activated and proliferating (Bockhold et al., 1998) 
Myf5 Activated and proliferating (Cornelison et al., 1997) 
MyoD Activated and proliferating, in  
 cells committed to myogenic program 
(Cornelison et al., 1997) 
Myogenin Early stages of differentiation (Charge et al., 2004; Hawke et al., 2001) 
MHC Terminal differentiation (Charge et al., 2004; Hawke et al., 2001) 
MRF4 Terminal differentiation (Charge et al., 2004; Hawke et al., 2001) 
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Appendix B: Representative immunohistochemical protocol 
 
 
 
Figure 1 Flow diagram of the immunohistochemical protocol followed in this study. 
See text for details. 
 
5% donkey serum at RT, 20′ 
Primary Ab at RT, 90′ 
FITC/Texas Red-linked Secondary Ab at RT, 30′ 
1/200 Hoechst at RT, 10′ 
1:1 Fixative methanol/acetone 
